<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Esomeprazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Esomeprazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Esomeprazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12431" href="/d/html/12431.html" rel="external">see "Esomeprazole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13281" href="/d/html/13281.html" rel="external">see "Esomeprazole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166971"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Esomep-EZS [DSC];</li>
<li>NexIUM;</li>
<li>NexIUM 24HR Clear Minis [OTC];</li>
<li>NexIUM 24HR [OTC];</li>
<li>NexIUM I.V.</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866789"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Esomeprazole;</li>
<li>M-Esomeprazole;</li>
<li>MYL-Esomeprazole;</li>
<li>MYLAN-Esomeprazole [DSC];</li>
<li>NexIUM;</li>
<li>PMS-Esomeprazole DR [DSC];</li>
<li>PMSC-Esomeprazole DR;</li>
<li>SANDOZ Esomeprazole;</li>
<li>TARO-Esomeprazole;</li>
<li>TEVA-Esomeprazole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166993"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Proton Pump Inhibitor;</li>
<li>
                        Substituted Benzimidazole</li></ul></div>
<div class="block doa drugH1Div" id="F166975"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All dosing is expressed in terms of esomeprazole base, regardless of the salt associated with the dosing information. Esomeprazole strontium 24.65 mg is equivalent to 20 mg of esomeprazole base; esomeprazole strontium 49.3 mg is equivalent to 40 mg of esomeprazole base.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis (off-label use): Oral:</b> 20 to 40 mg twice daily for an 8-week trial (Laserna-Mendieta 2020; Lucendo 2016; Philpott 2016). Once 8-week trial is complete and remission is achieved, the dose may be gradually lowered to an individualized maintenance level (Laserna-Mendieta 2020). Some experts initiate with once-daily dosing and increase to twice-daily dosing after 4 weeks if symptoms fail to improve (Bonis 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af13b8bc-31d9-4d53-ade6-d0f129e2f0f1">Gastroesophageal reflux disease, erosive or nonerosive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients with alarm symptoms (eg, dysphagia), referral to a specialist is recommended (ACG [Katz 2022]). For maximal efficacy, administer 30 to 60 minutes prior to a meal (Shin 2013). Maximal acid suppression is generally observed after ~3 days of continuous therapy (Shin 2013; Weisner 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Mild/intermittent disease (&lt;2 episodes/week) without erosive esophagitis or Barrett esophagus: </i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Some experts reserve proton pump inhibitors (PPIs) as alternatives to H<sub>2</sub>-receptor antagonists (H<sub>2</sub>RAs) for patients who have residual acid reflux symptoms despite twice-daily H<sub>2</sub>RA (Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 20 mg once daily for 4 to 8 weeks (ACG [Katz 2022]; Bayerdörffer 2016). <b>Note: </b>Some experts continue therapy until patient has been asymptomatic for 8 weeks (Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Severe and/or frequent symptoms (≥2 episodes/week) without erosive esophagitis or Barrett esophagus:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 20 to 40 mg once daily for 4 to 8 weeks (Hsu 2015; Kahrilas 2000). <b>Note: </b>Some experts use 20 mg once daily and continue therapy until patient has been asymptomatic for 8 weeks (Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Erosive esophagitis or Barrett esophagus</i>:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 40 mg once daily for 4 to 8 weeks then 20 mg once daily indefinitely, (ACG [Shaheen 2022]; AGA [Targownik 2022]; Labenz 2005; manufacturer's labeling) <b>or </b>20 mg once daily indefinitely (preferred by some experts) (Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (alternative route)</b>: 20 or 40 mg once daily for ≤10 days. <b>Note: </b>For use in patients with erosive esophagitis when oral therapy is not appropriate. Safety and efficacy have not been established for use &gt;10 days (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Residual symptoms despite 20 mg once daily:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Referral to a specialist is recommended<b>. </b>Options include doubling the PPI dose, switching to a different PPI, or adding an H<sub>2</sub>RA (Talley 2021). For patients requiring concomitant H<sub>2</sub>RA therapy, some experts administer the H<sub>2</sub>RA at bedtime (Fass 2022; Wang 2009); however, others advocate concurrent administration to ensure adherence (Abdul-Hussein 2015; Fandriks 2007; Sugimoto 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Recurrent symptoms after discontinuing acid suppression:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intermittent symptoms: </i>
<b>Oral: </b>20 mg once daily as needed (ACG [Katz 2022]; Bayerdörffer 2016; Zacny 2005). <b>Note: </b>Some experts do not recommend intermittent use due to reduced efficacy (Kahrilas 2022; Wolfe 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Persistent symptoms (eg consistent with symptoms at diagnosis):</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Recurrent symptoms after ≥3 months:</i> Repeat an 8-week course at the previously effective dose (Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Recurrent symptoms after &lt;3 months:</i> Long-term maintenance at the lowest effective dose necessary; referral to a specialist is recommended (ACG [Katz 2022]; Kahrilas 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>OTC labeling (patient-guided therapy): </b>Heartburn, frequent symptoms (≥2 episodes/week): <b>Oral:</b> 20 mg once daily for 14 days (maximum: 20 mg/day); may repeat 14-day course every 4 months if needed. Seek medical referral if symptoms do not resolve within 14 days of treatment; do not take for &gt;14 days or more often than every 4 months unless directed by a physician (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i></b>
<b> eradication:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Clarithromycin triple regimen: </i>20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days.<b> Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates ≥15%, eradication rates with clarithromycin-based regimens ≤85%) (ACG [Chey 2017]; Fallone 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bismuth quadruple regimen:</i> 20 mg twice daily in combination with tetracycline 500 mg 4 times daily, metronidazole 250 mg 4 times daily or 500 mg 3 or 4 times daily, and either bismuth subcitrate 120 to 300 mg 4 times daily or bismuth subsalicylate 300 mg 4 times daily; continue regimen for 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concomitant regimen: </i>20 mg twice daily in combination with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily; continue regimen for 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Sequential regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 5 to 7 days; then continue esomeprazole along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 5 to 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hybrid regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 7 days; then continue esomeprazole and amoxicillin along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Levofloxacin triple regimen:</i> 20 mg twice daily in combination with amoxicillin 1 g twice daily and levofloxacin 500 mg once daily; continue regimen for 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. Esomeprazole magnesium, esomeprazole strontium: 40 mg once daily. <b>Note:</b> Esomeprazole strontium capsules have been discontinued in the United States for &gt;1 year.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e280eae-968b-4264-8966-a95bec3faa0d">Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention:</b>
<b>Oral:</b> Esomeprazole magnesium, esomeprazole strontium: 20 to 40 mg once daily for up to 6 months; <b>Note:</b> 40 mg daily did not show additional benefit over 20 mg daily in clinical trials. Esomeprazole strontium capsules have been discontinued in the United States for &gt;1 year.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="938a412f-d439-4bc4-90c0-e2c4b1c17385">Nonsteroidal anti-inflammatory drug–induced gastric ulcers, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug–induced gastric ulcers, treatment (off-label use): Oral:</b> Esomeprazole magnesium: 20 mg once daily for 8 weeks (Goldstein 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fe1c098-0767-49b7-87df-f3a4952757ba">Pathological hypersecretory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pathological hypersecretory conditions (Zollinger-Ellison syndrome):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Esomeprazole magnesium, esomeprazole strontium: 40 mg twice daily; adjust regimen to individual patient needs; doses up to 240 mg daily have been administered. <b>Note:</b> Esomeprazole strontium capsules have been discontinued in the United States for &gt;1 year.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81764881-669d-4fcf-b906-df57e0a048e3">Peptic ulcer disease, treatment of complicated ulcers</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease, treatment of complicated ulcers (perforation, penetration, or gastric outlet obstruction) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 40 mg twice daily for 4 weeks, followed by 40 mg once daily. Duration depends on the location and etiology of ulcer (Vakil 2020c).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11220b85-ee52-4706-bb7b-6bdeebb826e9">Upper GI bleed, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper GI bleed, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pre-endoscopy (unknown etiology) (off label): Note: </b>Optimal proton pump inhibitor (PPI) therapy is uncertain. For patients with suspected active upper GI bleed, some experts suggest initiating high-dose IV PPI with continuous or intermittent dosing prior to endoscopy (ACG [Laine 2021]). Where IV PPIs are unavailable, high-dose oral PPI therapy is a reasonable alternative (ESGE [Gralnek 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion:</i>
<b>IV:</b> 80 mg bolus, followed by 8 mg/hour until endoscopy with subsequent dosing based on endoscopic findings (ACG [Laine 2021]; Barkun 2019; ESGE [Gralnek 2021]; Lau 2007; Liu 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent dosing:</i>
<b> IV:</b> 80 mg once (active bleeding) or 40 mg once (no evidence of active bleeding); if endoscopy is not performed within 12 hours, begin 40 mg every 12 hours until endoscopy. Subsequent dosing is based on endoscopic findings (ACG [Laine 2021]; ESGE [Gralnek 2021]; Leung 2022; Sachar 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (alternative route): </b>40 mg twice daily (ESGE [Gralnek 2021]; Keyvani 2006). <b>Note:</b> For select patients at low risk for rebleeding (ie, GBS of 0 to 1, clinically stable, timely access to medical care) who are to receive outpatient endoscopy, some experts use 20 mg once daily (Saltzman 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Postendoscopy (peptic ulcer hemorrhage): Note:</b> Treatment should address the underlying cause of the bleed. In patients with bleeding peptic ulcers, continue PPI therapy and direct further treatment at healing the ulcers and eliminating precipitating factors (eg, <i>H. pylori,</i> nonsteroidal anti-inflammatory drugs) (ACG [Laine 2021]; ESGE [Gralnek 2021]). <b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peptic ulcer with high-risk stigmata of recent hemorrhage (eg, active bleed, visible vessel, adherent clot):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Continuous infusion:</i>
<b>IV:</b> 80 mg bolus, followed by 8 mg/hour; if patient received 80 mg bolus prior to endoscopy, may omit bolus dose. Continue for ≥72 hours, then transition to high-dose oral maintenance therapy when able to tolerate (ACG [Laine 2021]; Barkun 2019; ESGE [Gralnek 2021]; Lau 2007; Liu 2012).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intermittent dosing (alternative administration):</i>
<b>IV:</b> 80 mg bolus once, then 40 mg every 12 hours; if 80 mg bolus was received prior to endoscopy, may omit bolus dose. Continue for ≥72 hours, then transition to high-dose oral maintenance therapy when able to tolerate (ACG [Laine 2021]; Barkun 2019; ESGE [Gralnek 2021]; Hsieh 2021; Leung 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance therapy:</i>
<b>Oral:</b> 40 mg twice daily for 14 days, followed by 40 mg once daily (ACG [Laine 2021]; Barkun 2019; ESGE [Gralnek 2021]; Sung 2014).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration: </i>The total duration of treatment depends on size, location, and cause of the ulcer and ranges from 4 to 12 weeks (ACG [Laine 2012]; Barkun 2010; Barkun 2019; Vakil 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peptic ulcer with clean base or flat pigmented spot: Note:</b> May transition to an oral PPI immediately after endoscopy (ACG [Laine 2021).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance therapy:</i>
<b>Oral:</b> 20 mg once daily (ACG [Laine 2012]; ACG [Laine 2021]; Saltzman 2022; Stanley 2019).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration:</i> The total duration of treatment depends on size, location, and cause of the ulcer and ranges from 4 to 12 weeks (ACG [Laine 2012]; Barkun 2010; Barkun 2019; Vakil 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b>
<b>Oral:</b> Some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 weeks to 4 weeks. If the patient is already on the lowest possible dose, alternate-day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be re-evaluated (Kim 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991014"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Kidney impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole magnesium: </i> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;1% excreted in the urine) (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole strontium:</i></p>
<p style="text-indent:-2em;margin-left:12em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:12em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended (has not been studied); strontium is eliminated by the kidney (manufacturer's labeling; expert opinion) and other esomeprazole formulations are available.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> No dosage adjustment necessary for any degree of kidney impairment (&lt;1% excreted in the urine) (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (highly protein bound) (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole magnesium: </i> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole strontium:</i> Use is not recommended (has not been studied); strontium is eliminated by the kidney (manufacturer's labeling) and other esomeprazole formulations are available.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (highly protein bound) (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole magnesium: </i> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole strontium:</i> Use is not recommended (has not been studied); strontium is eliminated by the kidney and other esomeprazole formulations are available.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole magnesium: </i> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole strontium:</i> Use is not recommended (has not been studied); strontium is eliminated by the kidney (manufacturer's labeling; expert opinion) and other esomeprazole formulations are available.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole magnesium: </i> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Esomeprazole strontium:</i> Use is not recommended (has not been studied); strontium is eliminated by the kidney (manufacturer's labeling; expert opinion) and other esomeprazole formulations are available.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> No dosage adjustment necessary (&lt;1% excreted in the urine) (manufacturer's labeling; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute kidney injury during therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Tubulointerstitial nephritis: Discontinue and evaluate patients if acute tubulointerstitial nephritis is suspected.</p></div>
<div class="block doha drugH1Div" id="F50988223"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C):</p>
<p style="text-indent:-2em;margin-left:6em;">Erosive esophagitis, <i>H. pylori</i> eradication or prevention of nonsteroidal anti-inflammatory drug–induced gastric ulcers: The manufacturer's labeling recommends a maximum dose of 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Pathological hypersecretory conditions (Zollinger-Ellison syndrome): Initial: 20 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of GERD (short-term):</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Dose should not exceed 20 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Upper GI bleed, acute (unknown etiology or peptic ulcer hemorrhage):</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion:</p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate impairment (Child-Pugh class A or B): 80 mg over 30 minutes, followed by a maximum continuous infusion of 6 mg/hour for a total of 72 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe impairment (Child-Pugh class C): 80 mg over 30 minutes, followed by a maximum continuous infusion of 4 mg/hour for a total of 72 hours.</p></div>
<div class="block doe drugH1Div" id="F166976"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Avoid use for &gt;8 weeks unless given for high-risk patients (eg, oral corticosteroid or chronic nonsteroidal anti-inflammatory drug use), patients with erosive esophagitis, Barrett esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F2934196"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13281" href="/d/html/13281.html" rel="external">see "Esomeprazole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37b54c5b-1a2f-475f-9fbf-0fd4f6025699">Erosive esophagitis associated with GERD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis associated with GERD:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants:</p>
<p style="text-indent:-2em;margin-left:8em;">3 to 5 kg: 2.5 mg once daily for up to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;5 to 7.5 kg: 5 mg once daily for up to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;7.5 kg: 10 mg once daily for up to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 11 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;20 kg: 10 mg once daily for 8 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">≥20 kg: 10 or 20 mg once daily for 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: 20 to 40 mg once daily for 4 to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: <b>Note:</b> Indicated only in cases where oral therapy is inappropriate or not possible; safety and efficacy &gt;10 days has not been established.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 0.5 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;55 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥55 kg: 20 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e4b52c-2ae7-4d5e-bc41-9d176e2d94e2">Gastroesophageal reflux disease, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, symptomatic: </b>
<b>Note: </b>Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: Infants, Children, and Adolescents: Oral: 0.7 to 3.3 mg/kg/<b>day</b> (AAP [Lightdale 2013]); maximum dose: 40 mg/dose (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing (NASPGHAN/ESPGHAN [Rosen 2018]): Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: 20 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori</b></i>
<b> eradication (NASPGHAN/ESPGHAN [Jones 2017]):</b> Children and Adolescents: Oral: <b>Note:</b> Usual duration of therapy is 14 days as part of triple therapy; use in combination with 2 antimicrobials (eg, clarithromycin, metronidazole, amoxicillin); preferred agents determined by susceptibility. Bismuth may be added to regimens as an alternative if resistance is present or susceptibility is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">15 to &lt;25 kg: 20 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">25 to 34 kg: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;34 kg: 40 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Oral: Based on experience in adults, some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 to 4 weeks. If the patient is already on the lowest possible dose, alternate day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be reevaluated (Kim 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109278"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: Oral, IV: No dosage adjustments necessary.</p></div>
<div class="block dohp drugH1Div" id="F51128335"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific pediatric recommendations; based on experience in adult patients, adjustment suggested in severe impairment.</p></div>
<div class="block arsc drugH1Div" id="F58119782"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cutaneous and systemic lupus erythematosus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous lupus erythematosus</b>, most often subacute cutaneous lupus erythematosus (SCLE), has been reported with use of proton pump inhibitors (PPIs), including esomeprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-32607016','lexi-content-ref-23548825','lexi-content-ref-35198470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-32607016','lexi-content-ref-23548825','lexi-content-ref-35198470'])">Ref</a></span>). SCLE is reversible (resolution ~3 months following discontinuation [range: 4 weeks to 8 months]), and cross-reactivity between PPIs has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35198470','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35198470','lexi-content-ref-24547721'])">Ref</a></span>). SCLE may present as a widespread skin rash which may include bullous lesions and focal skin necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35198470','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35198470','lexi-content-ref-24547721'])">Ref</a></span>). In addition, <b>systemic lupus erythematosus</b> secondary to PPIs may occur, although less often as compared to SCLE. Presentation often includes rash; however, arthralgia or cytopenia may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. SCLE is typically associated with positive antinuclear antibodies, anti-Ro/SSA, and anti-La/SSB antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23548825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23548825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied.</p>
<p style="text-indent:-2em;margin-left:6em;">Cutaneous lupus erythematosus: Approximately 8 months following treatment initiation (range: 3 days to 3.5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-35198470','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-35198470','lexi-content-ref-24547721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Systemic lupus erythematosus: According to the manufacturer, may occur within days to years after initiating treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history or family history of SCLE, especially secondary to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-24547721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for SCLE (eg, female of childbearing age, periods of female hormone changes, prior history of drug allergies, sun-reactive skin, exposure to UV radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Enteric infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including esomeprazole, may increase risk of enteric infections in adult and pediatric patients, including gastroenteritis and <b>
<i>Clostridioides difficile-</i>associated diarrhea </b>(CDAD); however, data are conflicting, especially with regard to CDAD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16651285','lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-25112692','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-20047577','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16651285','lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-25112692','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-20047577','lexi-content-ref-28054368'])">Ref</a></span>). <b>Diarrhea</b>, which may be a result of enteric infection, is the most common adverse effect secondary to long-term PPI use and often results in treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>). Consider CDAD diagnosis in patients with persistent diarrhea that does not improve, especially in hospitalized patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368'])">Ref</a></span>); related to the pharmacologic action. The increase in gastric pH secondary to PPI administration leads to changes in intestinal microbial environment which may allow for intestinal germination and growth of <i>C. difficile </i>spores, as well as colonization by other bacteria responsible for enteric infections (eg, <i>Salmonella</i>, <i>Campylobacter</i>, <i>Shigella</i>, norovirus) and multidrug-resistant microorganisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-28325163','lexi-content-ref-32091544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-28325163','lexi-content-ref-32091544'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hospitalized patients receiving high doses may experience CDAD within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31187275'])">Ref</a></span>), whereas others develop gastroenteritis with long-term therapy in the community setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243','lexi-content-ref-28054368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (eg, daily or more frequently than daily use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28842261','lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28842261','lexi-content-ref-31187275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infants and children with defective immune systems or indwelling catheters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25752807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25752807'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including esomeprazole, may increase the risk of <b>bone</b>
<b>fracture</b> in children, young adults, and older adults, including osteoporosis-related fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26209167','lexi-content-ref-25986385','lexi-content-ref-31175146','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26209167','lexi-content-ref-25986385','lexi-content-ref-31175146','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276'])">Ref</a></span>). However, data regarding the impact of PPIs on fractures, as well as bone mineral density (BMD), are inconclusive and some have concluded that any association with fracture may be related to other independent risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30445008','lexi-content-ref-36142643','lexi-content-ref-30237993','lexi-content-ref-23455632','lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30445008','lexi-content-ref-36142643','lexi-content-ref-30237993','lexi-content-ref-23455632','lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (hypergastrinemia and hypochlorhydria). Hypergastrinemia causes secondary hyperparathyroidism which can increase bone resorption and subsequent decreased BMD. Hypochlorhydria results in decreased absorption of calcium, magnesium, and vitamin B<sub>12</sub>. Impaired calcium absorption may cause secondary hyperparathyroidism and decreased BMD. Decreased vitamin B<sub>12</sub> absorption may decrease osteoblastic activity leading to decreased BMD, as well as decreased collagen cross-linking leading to weakened bone structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for fractures and/or osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (eg, ≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179','lexi-content-ref-32176276'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (≥1.5 doses per day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20353792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20353792'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric: Initiation of therapy at age &lt;1 year or ≥6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31175146','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31175146','lexi-content-ref-32176276'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric: Concurrent use of PPI plus H<sub>2</sub> blocker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31175146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31175146'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fundic gland polyps</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs), including esomeprazole, has been associated with the development of reversible <b>gastric polyp </b>(fundic gland) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16240222','lexi-content-ref-17059515','lexi-content-ref-32718584','lexi-content-ref-26209527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16240222','lexi-content-ref-17059515','lexi-content-ref-32718584','lexi-content-ref-26209527'])">Ref</a></span>). Most PPI users who developed fundic gland polyps were asymptomatic. Symptomatic patients may report nausea, vomiting, or abdominal pain. GI bleeding and/or anemia may occur with ulcerated polyp. Clinicians should note that <i>Helicobacter pylori </i>infection may be protective against fundic gland polyps as bacterial proteases help glandular outflow by breaking down blockages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; long-term use of PPIs is associated with an increase in the prevalence of parietal cell protrusions which cause outflow blockage of the isthmus and subsequent formation of fundic gland cysts. As therapy continues, fundic gland cysts may enlarge and develop into fundic gland polyps (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with familial adenomatous polyposis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment (&gt;1 year and especially ≥5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions secondary to proton pump inhibitors (PPIs) are rare and range from <b>urticaria</b> and <b>angioedema</b> to <b>anaphylaxis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22697020','lexi-content-ref-24267357','lexi-content-ref-30675130','lexi-content-ref-29872353','lexi-content-ref-21626263','lexi-content-ref-33089794','lexi-content-ref-19274931','lexi-content-ref-33031621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22697020','lexi-content-ref-24267357','lexi-content-ref-30675130','lexi-content-ref-29872353','lexi-content-ref-21626263','lexi-content-ref-33089794','lexi-content-ref-19274931','lexi-content-ref-33031621'])">Ref</a></span>). Delayed hypersensitivity reactions include <b>maculopapular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23134998','lexi-content-ref-28658503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23134998','lexi-content-ref-28658503'])">Ref</a></span>), as well as rare severe cutaneous adverse reactions (SCARs), such as <b>acute generalized exanthematous pustulosis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29894542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29894542'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>fixed drug eruption,</b>
<b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24751668','lexi-content-ref-17711546','lexi-content-ref-27134114','lexi-content-ref-28658503','lexi-content-ref-32933772','lexi-content-ref-30051945','lexi-content-ref-31967328','lexi-content-ref-33031621','lexi-content-ref-19659985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24751668','lexi-content-ref-17711546','lexi-content-ref-27134114','lexi-content-ref-28658503','lexi-content-ref-32933772','lexi-content-ref-30051945','lexi-content-ref-31967328','lexi-content-ref-33031621','lexi-content-ref-19659985'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria): IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24267357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24267357'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (including maculopapular rash and SCARs): T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-21470217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-21470217'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-24267357','lexi-content-ref-24834779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-24267357','lexi-content-ref-24834779'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Maculopapular reactions: Intermediate; generally occurs 7 to 10 days after initiation, but may occur up to 1 month following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28658503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28658503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Other reactions (including SCARs): Varied; occurs after 7 to 14 days up to 3 months following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-24751668','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-24751668','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of hypersensitivity reaction to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16440530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16440530'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity has been noted with PPIs, although cross-reactivity patterns have been variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30058396','lexi-content-ref-24267357','lexi-content-ref-17711546','lexi-content-ref-24659167','lexi-content-ref-33089794','lexi-content-ref-24834779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30058396','lexi-content-ref-24267357','lexi-content-ref-17711546','lexi-content-ref-24659167','lexi-content-ref-33089794','lexi-content-ref-24834779'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypomagnesemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs), including esomeprazole, has resulted in reversible <b>hypomagnesemia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33751184','lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584','lexi-content-ref-22122397','lexi-content-ref-22745572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33751184','lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584','lexi-content-ref-22122397','lexi-content-ref-22745572'])">Ref</a></span>); rate of occurrence may be highest with omeprazole as compared to other PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33751184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33751184'])">Ref</a></span>). Symptoms may be severe (eg, tetany, cardiac arrhythmias, cerebellar syndrome, seizures) and resistant to treatment with supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675'])">Ref</a></span>). May require discontinuation of PPI in addition to magnesium supplementation in ~25% of patients. Following discontinuation, magnesium normalizes after ~1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). Hypomagnesemia may recur if PPI therapy is restarted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-21930865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-21930865'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; the specific mechanism is unknown; however, long-term use of PPIs may be associated with changes in intestinal absorption of magnesium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; hypomagnesemia occurs most often after 1 year of therapy but may occur as early as 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). In patients with prior PPI-induced hypomagnesemia, re-initiation may result in recurrence within 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥3 months and especially &gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other drugs that cause hypomagnesemia (eg, loop diuretics, thiazide diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who have undergone kidney transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31817776','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31817776','lexi-content-ref-FDA.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Interstitial nephritis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute interstitial nephritis</b> (AIN) may occur rarely with use of proton pump inhibitors (PPIs), including esomeprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15748135','lexi-content-ref-17635502','lexi-content-ref-23960351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15748135','lexi-content-ref-17635502','lexi-content-ref-23960351'])">Ref</a></span>), with renal biopsy showing diffuse interstitial infiltrate and tubulitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>). Patients generally achieve complete or partial recovery by 6 months following treatment of AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24927897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24927897'])">Ref</a></span>). Signs of systemic hypersensitivity (fever, rash, eosinophilia) often seen in other cases of drug-induced AIN are <b>not</b> typically observed in proton pump inhibitor (PPI)-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611','lexi-content-ref-24927897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611','lexi-content-ref-24927897'])">Ref</a></span>). Clinicians should note that there appears to be <b>no</b> correlation between duration of exposure to PPI and duration or severity of acute kidney failure after resolution of AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; unknown although may be immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>) or idiosyncratic, with direct toxic effect on tubular cells demonstrated with omeprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32092686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32092686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; usually occurs within 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611'])">Ref</a></span>) although has been reported to occur up to 10 months with other PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073','lexi-content-ref-21143456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073','lexi-content-ref-21143456'])">Ref</a></span>). Upon reexposure symptoms often present more rapidly, often within 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults; although this may be due to increased use of PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactions among PPIs in patients who developed AIN is not known</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of a PPI may increase the risk of immune checkpoint inhibitor-induced nephritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34410975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34410975'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vitamin B12 deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of acid suppressive therapies, including esomeprazole, may result in reversible <b>vitamin B<sub>12</sub> deficiency</b>; however, data regarding the clinical significance of these changes and causality are conflicted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038','lexi-content-ref-29610598','lexi-content-ref-30792587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038','lexi-content-ref-29610598','lexi-content-ref-30792587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; acid suppressive therapies interfere with acid-activated proteolytic digestion of dietary protein-bound vitamin B<sub>12</sub> in the stomach, thereby resulting in malabsorption of vitamin B<sub>12 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-24327038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥2 to 3 years); the association between ≥2 years of proton pump inhibitor (PPI) use and vitamin B<sub>12</sub> deficiency was stronger among people &lt;30 years of age and in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (≥1.5 pills per day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038','lexi-content-ref-9626024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038','lexi-content-ref-9626024'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for vitamin B<sub>12</sub> deficiency (eg, malnourished patients, vegan diet) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-21365243'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F166938"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are for the oral formulation in adults unless otherwise indicated; IV formulation reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (IV: 11%; oral: children, adolescents, adults: 2% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (IV: 1%; oral: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered thyroid hormone levels (increased thyroxine: ≤1%), decreased serum potassium (≤1%), decreased serum sodium (≤1%), decreased thyroid hormones (thyroxine: ≤1%), increased serum potassium (≤1%), increased serum sodium (≤1%), increased thyroid stimulating hormone level (≤1%), increased uric acid (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (IV: 6%; oral: infants, children, adolescents, adults: 1% to 4%), acid regurgitation (infants: 1%), constipation (IV: 3%; oral: ≥1%), diarrhea (IV: 4%; oral: children, adolescents, adults: 2% to 4%), flatulence (IV: 10%; oral: ≥1%), increased gastrin (≤1%), nausea (IV: 6%; oral: adolescents, adults: 2%), vomiting (infants: ≥5%; adults: &lt;1%), xerostomia (IV: 4%; oral: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased hemoglobin (≤1%), quantitative disorders of platelets (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (infants, adults: ≤1%), increased serum alkaline phosphatase (≤1%), increased serum aspartate aminotransferase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (IV: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (IV: ≤3%; oral: &lt;1%), drowsiness (children: 2%; adults: &lt;1%), irritability (infants: ≥5%), vertigo (IV: ≤3%; oral: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (IV: 1%; oral: &lt;1%), tachypnea (infants: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (IV: 4%; oral: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, edema, flushing, hypertension, lower extremity edema, peripheral edema, substernal pain, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, dermatitis, diaphoresis, erythematous rash, maculopapular rash, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, goiter, hot flash, hyperuricemia, hyponatremia, increased thirst, menstrual disease, vitamin B<sub>12</sub> deficiency, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, anorexia, aphthous stomatitis, change in bowel habits, dysgeusia, dysphagia, enlargement of abdomen, eructation, exacerbation of constipation, gastroenteritis, gastrointestinal hemorrhage, hernia of abdominal cavity, hiccups, increased appetite, melena, mouth disease, pruritus ani, rectal disease, tongue disease</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dysmenorrhea, dysuria, erectile dysfunction, genitourinary fungal infection, glycosuria, hematuria, polyuria, urinary frequency, urine abnormality, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, cervical lymphadenopathy, gastrointestinal dysplasia, hypochromic anemia, leukocytosis, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, facial edema, hypersensitivity reaction, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (including esophageal candidiasis [Ma 2020], gastrointestinal candidiasis, genital candidiasis, and urogenital candidiasis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, apathy, asthenia, confusion, exacerbation of depression, fatigue, fibromyalgia syndrome, hypertonia, hypoesthesia, insomnia, malaise, migraine (including exacerbation of migraine headache), nervousness, pain, paresthesia, rigors, sleep disorder, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, exacerbation of arthritis, muscle cramps, polymyalgia rheumatica</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, visual disturbance, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, otitis media, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, epistaxis, exacerbation of asthma, flu-like symptoms, laryngeal edema, pharyngeal disease, pharyngitis, rhinitis, sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Barrett esophagus, benign gastric nodule, benign polyp of stomach, duodenitis, esophageal stenosis, esophageal ulcer, esophageal varices, mucosal discoloration</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, alopecia, cutaneous lupus erythematosus (including exacerbations) (Kaur 2022), erythema multiforme, fixed drug eruption (Salloum 2020), hyperhidrosis, skin photosensitivity (Shukla 2010), Stevens-Johnson syndrome (Lin 2020), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, hypomagnesemia (Negri 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (Wade 2014), colitis (microscopic) (Wilcox 2009), gastric polyp (fundic gland) (Flick 2005), pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Dury 2012), pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic encephalopathy, hepatic failure, hepatitis (Zaccardi 2014), hepatotoxicity (idiosyncratic) (Chalasani 2014; Thomas 2016), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Li 2020), drug reaction with eosinophilic and systemic symptoms (Caboni 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, depression, hallucination, myasthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Lespessailles 2022), myalgia (Grattaliano 2005), osteonecrosis of the jaw (Marconcini 2019); rhabdomyolysis (Jeon 2016), systemic lupus erythematosus (including exacerbation of systemic lupus erythematous; Rowell syndrome [Almansouri 2020])</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (including acute interstitial nephritis [Geevasinga 2005]), kidney disease (chronic) (Lazarus 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p></div>
<div class="block coi drugH1Div" id="F166951"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to esomeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; concomitant use with products that contain rilpivirine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if you have trouble or pain when swallowing food; vomiting with blood, or bloody or black stools; heartburn with light-headedness, dizziness, or sweating; chest pain or shoulder pain with shortness of breath, sweating, pain spreading to arms, neck or shoulders, or light-headedness; frequent chest pain.</p></div>
<div class="block war drugH1Div" id="F166936"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with severe hepatic impairment may require dosage reductions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Pharmacokinetics of esomeprazole are not expected to be altered in renal impairment; dosage adjustments are not necessary for any degree of renal impairment when using esomeprazole magnesium or esomeprazole sodium. However, since clearance of strontium is reduced in mild to moderate renal impairment, esomeprazole strontium is not recommended for use in severe impairment (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bioavailability may be increased in older adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Esomeprazole strontium: Strontium competes with calcium for intestinal absorption and is incorporated into bone; use of esomeprazole strontium in pediatric patients is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intravenous: Safety and efficacy of IV treatment for GERD beyond 10 days have not been established; transition from IV to oral therapy as soon possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (≤7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop esomeprazole treatment ≥14 days before CgA test; if CgA level high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), notify health care provider before use if any of the following are present: heartburn for &gt;3 months; frequent wheezing, particularly with heartburn; unexplained weight loss; nausea or vomiting; or stomach pain. Discontinue use and notify health care provider if heartburn continues or worsens; diarrhea occurs; if &gt;14 days of therapy is needed; or if &gt;1 course of therapy is needed every 4 months.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53208401"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use of gastric acid inhibitors, including proton pump inhibitors, has been associated with community-acquired pneumonia in pediatric patients 4 to 36 months of age (Canani 2006). Routine use in preterm infants is not recommended (AAP [Eichenwald 2018]).</p></div>
<div class="block prod-avail drugH1Div" id="F58332934"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Esomeprazole strontium capsules have been discontinued in the United States for &gt;1 year.</p></div>
<div class="block dosfc drugH1Div" id="F22149198"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole strontium 49.3 mg is equivalent to 40 mg of esomeprazole base.</p>
<p style="text-indent:-2em;margin-left:2em;">Esomep-EZS Kit contains delayed release capsules, packaged with Pill Swallowing Spray</p></div>
<div class="block foc drugH1Div" id="F166946"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM: 20 mg, 40 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM 24HR: 20 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM 24HR Clear Minis: 20 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as strontium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 49.3 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Esomep-EZS: 20 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM: 2.5 mg (30 ea); 5 mg (30 ea); 10 mg (30 ea); 20 mg (30 ea); 40 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (30 ea); 20 mg (1 ea, 30 ea); 40 mg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM I.V.: 40 mg (1 ea) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM 24HR: 20 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F166932"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F166954"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Esomeprazole Magnesium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.42 - $9.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.28 - $9.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (NexIUM 24HR Clear Minis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (NexIUM 24HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (NexIUM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $11.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $11.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Esomeprazole Magnesium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $9.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $9.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $9.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (NexIUM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $11.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $11.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $11.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $11.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Esomeprazole Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $41.88 - $60.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (NexIUM I.V. Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $53.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (NexIUM 24HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866790"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM: 10 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as magnesium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM: 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexIUM: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p></div>
<div class="block adm drugH1Div" id="F166948"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Swallow whole; do not chew or crush; take at least 1 hour before eating (best if taken before breakfast). Capsule can be opened and contents mixed with 1 tablespoon of applesauce. Swallow immediately; mixture should not be chewed or warmed. Do not store mixture for future use. For patients with difficulty swallowing, use of granules may be more appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Take at least 1 hour before eating. Empty the 2.5 mg or 5 mg packet into a container with 5 mL of water or the 10 mg, 20 mg, or 40 mg packet into a container with 15 mL of water (use double the amount of water if 2 packets are needed) and stir; leave 2 to 3 minutes to thicken. Stir and drink within 30 minutes. If any medicine remains after drinking, add more water, stir and drink immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Swallow whole; do not crush or chew; administer with a full glass of water before breakfast in the morning.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet [Canadian product]: Swallow whole with water or may be dispersed in a half a glass of noncarbonated water. Stir until tablets disintegrate, and drink the liquid with pellets immediately or within 30 minutes. Do not chew or crush pellets. After drinking, rinse glass with water and drink.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release tablet cannot be cut or crushed. Switch to delayed-release capsule since capsule can be opened and contents sprinkled onto soft food of choice as long as patient does not chew the mixture.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Flush line prior to and after administration with NS, LR, or D<sub>5</sub>W.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of GERD: May be administered by injection (≥3 minutes), or intermittent infusion (10 to 30 minutes)</p>
<p style="text-indent:-2em;margin-left:4em;">Upper GI bleed, acute (unknown etiology or peptic ulcer hemorrhage): May be administered as continuous infusion or intermittent infusion (infuse over 30 minutes), depending on risk of rebleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasogastric tube:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Open capsule and place intact granules into a 60 mL catheter-tip syringe; mix with 50 mL of water. Replace plunger and shake vigorously for 15 seconds. Ensure that no granules remain in syringe tip. Do not administer if pellets dissolve or disintegrate. Use immediately after preparation. After administration, flush nasogastric tube with additional water.</p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Delayed release oral suspension granules can also be given by nasogastric or gastric tube. If using a 2.5 mg or 5 mg packet, first add 5 mL of water to a catheter-tipped syringe, then add granules from packet. If using a 10 mg, 20 mg, or 40 mg packet, first add at least 15 mL of water to a catheter-tipped syringe, then add granules from packet. Shake the syringe, leave 2 to 3 minutes to thicken. Shake the syringe and administer through nasogastric or gastric tube (size 6 French or greater) within 30 minutes. Refill the syringe with equal amount (5 mL or 15 mL) of water, shake and flush nasogastric/gastric tube.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet [Canadian product]: Dispersed tablets can also be given by nasogastric tube (size 8 to 20 French) using a 25 to 60 mL disposable syringe. Disperse tablet in 50 mL of water. After administration, flush with additional 25 to 50 mL of water to clear the syringe and tube. In larger nasogastric feeding tubes (ie, size 14 French or greater), the dispersion volume may be reduced to 25 mL.</p></div>
<div class="block admp drugH1Div" id="F52612731"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer at least 1 hour before food or meals</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Swallow whole, do not chew or crush. For patients with difficulty swallowing the capsule, capsule may be opened and the enteric coated pellets may be mixed with 1 tablespoon of applesauce (applesauce should not be hot) and swallowed immediately; do not chew or crush granules; do not store mixture for future use.</p>
<p style="text-indent:-2em;margin-left:6em;">Nasogastric tube administration: Open capsule and place intact granules into a 60 mL catheter-tipped syringe; mix with 50 mL of water. Replace plunger and shake vigorously for 15 seconds. Ensure that no granules remain in syringe tip. Do not administer if pellets dissolve or disintegrate. Use immediately after preparation. After administration, flush nasogastric tube with additional water.</p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Mix contents of the 2.5 mg or 5 mg packet with 5 mL of water or the 10 mg, 20 mg, or 40 mg packet with 15 mL water and stir; leave for 2 to 3 minutes to thicken; stir and drink within 30 minutes. If any medicine remains after drinking, add more water, stir and drink immediately.</p>
<p style="text-indent:-2em;margin-left:6em;">Nasogastric or gastric tube administration: If using a 2.5 mg or 5 mg packet, first add 5 mL of water to a catheter-tipped syringe, then add granules from packet. If using a 10 mg, 20 mg, or 40 mg packet, first add 15 mL of water to a catheter-tipped syringe, then add granules from packet. Shake the syringe, leave 2 to 3 minutes to thicken. Shake the syringe and administer through nasogastric or gastric tube (French size 6 or greater) within 30 minutes. Refill the syringe with an equal amount (5 mL or 15 mL) of water, shake and flush tube.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Flush line prior to and after administration with NS, LR, or D5W. Administer desired dose by intermittent infusion over 10 to 30 minutes. The manufacturer recommends that pediatric patients receive intravenous esomeprazole by intermittent infusion only.</p></div>
<div class="block uica drugH1Div" id="F14472623"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 20 mg in 50 mL (concentration: 0.4 mg/mL) <b>or</b> 40 mg in 50 mL (concentration: 0.8 mg/mL) of D<sub>5</sub>W, LR, or NS</p></div>
<div class="block meg drugH1Div" id="F15241701"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Esomeprazole strontium delayed release capsules: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F202342s006lbl.pdf%23page%3D29&amp;token=NJrr3jLeUmM%2BwbPMqAfRkDYT2U9zgTuQ%2BhY4%2FstlS9puNTZj%2BI1wCtF8mvx%2F0pqKUCmL4eSvXh2WI4FQ4SJkupv7DNwyk8JMreNLA2M8tJ0%2B3XKOxocyW5tyDP31OtZt&amp;TOPIC_ID=9104" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202342s006lbl.pdf#page=29</a></p>
<p style="text-indent:-2em;margin-left:4em;">NexIUM capsules, granules for oral suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021153s060%2C021957s027%2C022101s024lbl.pdf%23page%3D40&amp;token=8TUrEYZnCCLrqtLlo%2B4ZVLhjW%2FAC36HVQq1AYRlPfRzJzV0GqbtaUmM2uMbx3vb1QUuTXuWe7bBGKXdP9sqaAjbxiaa4k1Olv4iqV%2BU9dOkRBQyvINUW77gjbtAHNVx5AaymimHWp%2BJj0xCPzbVM5Q%3D%3D&amp;TOPIC_ID=9104" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021153s060,021957s027,022101s024lbl.pdf#page=40</a></p></div>
<div class="block use drugH1Div" id="F166947"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Upper GI bleed, acute, postendoscopy:</b> Decrease the risk of rebleeding after successful endoscopy for acute bleeding gastric or duodenal ulcers in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole magnesium:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Healing of erosive esophagitis:</b> Short-term (4 to 8 weeks in adults and pediatric patients 12 to 17 years of age; 8 weeks in pediatric patients 1 to 11 years of age; or up to 6 weeks in pediatric patients 1 month to &lt;1 year of age) treatment of erosive esophagitis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance of healing of erosive esophagitis:</b> Maintaining symptom resolution and healing of erosive esophagitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Symptomatic gastroesophageal reflux disease:</b> Short-term (4 to 8 weeks in adults; 4 weeks in pediatric patients 12 to 17 years of age; or up to 8 weeks in pediatric patients 1 to 11 years of age) treatment of symptomatic gastroesophageal reflux disease (GERD).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heartburn (OTC labeling):</b> Treatment of frequent heartburn (≥2 days per week).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Helicobacter pylori</i></b>
<b> eradication (Rx only):</b> As part of a multidrug regimen for <i>H. pylori</i> eradication in adults with duodenal ulcer disease (active or history of within the past 5 years).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (Rx only):</b> Treatment (long term) of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Risk reduction of nonsteroidal anti-inflammatory drug-associated gastric ulcer (Rx only):</b> Prevention of gastric ulcers associated with continuous nonsteroidal anti-inflammatory drug (NSAID) therapy in adults at risk (age ≥60 years and/or history of gastric ulcer).</p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole strontium:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastroesophageal reflux disease:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Healing of erosive esophagitis:</b> Short-term (4 to 8 weeks) treatment of erosive esophagitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance of healing of erosive esophagitis:</b> Maintaining symptom resolution and healing of erosive esophagitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Symptomatic gastroesophageal reflux disease:</b> Short-term (4 to 8 weeks) treatment of symptomatic GERD in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>H. pylori</b></i>
<b> eradication:</b> As part of a multidrug regimen for <i>H. pylori</i> eradication in adults with duodenal ulcer disease (active or history of within the past 5 years).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pathological hypersecretory conditions, including Zollinger-Ellison syndrome:</b> Treatment (long term) of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Risk reduction of nonsteroidal anti-inflammatory drug-associated gastric ulcer:</b> Prevention of gastric ulcers associated with continuous NSAID therapy in adults at risk (≥60 years of age and/or history of gastric ulcer).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV:</b> Esomeprazole sodium:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gastroesophageal reflux disease (Rx only):</b> Short-term (≤10 days) treatment of GERD with erosive esophagitis in pediatric patients 1 month to 17 years of age and adults when oral therapy is not possible or appropriate.</p></div>
<div class="block off-label drugH1Div" id="F50558978"><span class="drugH1">Use: Off-Label: Adult</span><p>Eosinophilic esophagitis; Peptic ulcer disease, treatment of complicated ulcers; Stress ulcer prophylaxis in critically ill patients; Treatment of NSAID-induced gastric ulcers; Upper GI bleed, acute (unknown etiology or peptic ulcer hemorrhage), pre-endoscopy</p></div>
<div class="block mst drugH1Div" id="F5730363"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Esomeprazole may be confused with ARIPiprazole, omeprazole</p>
<p style="text-indent:-2em;margin-left:4em;">NexIUM may be confused with NexAVAR</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Esomeprazole is identified in the Beers Criteria as a potentially inappropriate medication to be avoided (as scheduled use for &gt;8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection, pneumonia, GI malignancies, and bone loss/fractures <i>unless</i> given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H2 blockers) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F166987"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak), OAT1/3</p></div>
<div class="block dri drugH1Div" id="F166940"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Acalabrutinib. This interaction is only applicable to acalabrutinib capsules. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Atazanavir.  Management: Avoid use in treatment-experienced patients. In treatment-naive patients, administer boosted atazanavir 12 hours after the PPI and the PPI dose should not exceed the equivalent of 20 mg omeprazole. Monitor for reduced atazanavir efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: Esomeprazole may increase serum concentrations of the active metabolite(s) of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Esomeprazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with esomeprazole. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation, etc.).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Esomeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dacomitinib.  Management: Avoid concurrent use of dacomitinib with PPIs and PCABs. Antacids may be used. Histamine H2-receptor antagonists (HR2A) may be used if dacomitinib is given at least 6 hours before or 10 hours after the H2RA.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with PPIs or PCABs should be avoided in patients treated with delavirdine. The clinical significance of short-term PPI or PCAB therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the bioavailability of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Esomeprazole may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Gefitinib.  Management: Avoid use of inhibitors of the proton pump (PPIs or PCABs) with gefitinib when possible. If required, administer gefitinib 12 hours after the PPI/PCAB or 12 hours before the next dose of the PPI/PCAB. Closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Infigratinib. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics).  Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).  Management: Administer ketoconazole with an acidic beverage, such as non-diet cola, to increase gastric acidity and improve absorption if concomitant use with proton pump inhibitors or potassium-competitive acid blockers is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Ledipasvir.  Management: PPI  or PCAB doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Use of ledipasvir with higher doses or with food, or 2 hours after a these agents, may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Levoketoconazole. Levoketoconazole may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.  Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nelfinavir.  Management: Due to potentially significant reductions in nelfinavir exposure, avoid concurrent use of nelfinavir with a PPI or PCAB when possible. If unavoidable, consider PPI or PCAB use for a short duration (less than 30 days) and closely monitor viral load.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nilotinib.  Management: Avoid this combination. Histamine H2 receptor antagonists (H2RAs) given 10 hours before or 2 hours after nilotinib, or antacids given 2 hours before or 2 hours after nilotinib are acceptable alternatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Palbociclib. Specifically, this has been reported with the use of palbociclib capsules. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Palbociclib. Specifically, this may occur with the use of palbociclib capsules, and to the greatest extent when taken without food.  Management: Carefully evaluate potential risks and benefits of coadministration of palbociclib capsules and proton pump inhibitors or potassium-competitive acid blockers due to the risk of reduced palbociclib efficacy. Palbociclib capsules should be taken with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Pexidartinib.  Management: Avoid this combination. If acid-reduction is needed, consider administering an antacid 2 hours before or after pexidartinib, or administer pexidartinib 2 hours before or 10 hours after an H2 receptor antagonist.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Posaconazole.  Management: Avoid coadministration of PPIs or PCABs and posaconazole oral suspension. Posaconazole delayed-release tablets do not appear to be sensitive to this interaction and do not required dose adjustment if coadministered with PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.  Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and PPIs or PCABs should be avoided. If coadministration cannot be avoided, selpercatinib and PPIs or PCABs should be administered simultaneously with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Esomeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Sestamibi: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Sestamibi.  Management: Consider holding/stopping proton pump inhibitor therapy for at least 3 days prior to the use technetium Tc 99m sestamibi in cardiac imaging procedures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tetrofosmin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Inhibitors of the Proton Pump (PPIs and PCABs) may enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Velpatasvir.  Management: Sofosbuvir/velpatasvir should be administered with food and taken 4 hours before omeprazole 20 mg. Sofosbuvir/velpatasvir/voxilaprevir can be administered with omeprazole 20 mg. Use with other PPIs or PCABs has not been studied.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Esomeprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F166968"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>
<div class="block pri drugH1Div" id="F166955"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Esomeprazole crosses the placenta (Saito 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Following a maternal dose of esomeprazole 10 mg/day throughout pregnancy, cord blood concentrations at delivery were ~40% of those in the maternal serum (~12 hours after the last maternal dose). Twelve hours after delivery (~23 hours after the last maternal dose), esomeprazole was no longer detected in the infant serum (Saito 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following use of proton pump inhibitors (PPIs) during pregnancy are available (Choi 2023; Hussain 2022; Peron 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of esomeprazole may be altered. Data from a single dose study of esomeprazole in patients with preterm preeclampsia suggest clearance may be decreased, possibly due to inhibition of CYP2C19 (Gebreyesus 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for the treatment of gastroesophageal reflux disease in pregnant patients are available. When initiating treatment during pregnancy, a step-up approach, starting with diet and lifestyle modifications, is recommended. PPIs are considered acceptable for use during pregnancy when other medications are not effective (Ali 2022; Dunbar 2022; Thélin 2020).</p></div>
<div class="block brc drugH1Div" id="F166956"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole is present in breast milk (Saito 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">A case report describes maternal use of esomeprazole 10 mg/day throughout pregnancy and postpartum. Breast milk was sampled multiple times between 2 and 4 days after delivery at term. The highest breast milk concentration was 4 hours after the maternal dose (19.6 ng/mL) and esomeprazole was no longer detected in breast milk 10 hours after the maternal dose. Using the highest breast milk concentration, authors of the study determined the estimated daily infant dose via breast milk to be 0.003 mg/kg/day. This infant received &gt;50% of nutrition via breast milk and was developing normally as of 6 months of age (Saito 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F166957"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take at least 1 hour before meals; best if taken before breakfast.</p></div>
<div class="block mop drugH1Div" id="F166944"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Susceptibility testing recommended in patients who fail <i>H. pylori</i> eradication regimen. Monitor for rebleeding in patients with upper GI bleeding or peptic ulcer bleed. Magnesium (baseline and periodically thereafter; especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia), calcium (baseline and periodically in patients at risk [eg, hypoparathyroidism]); signs or symptoms of cutaneous lupus erythematosus or systemic lupus erythematosus; <i>C. difficile</i>-associated diarrhea; bone loss and fractures (especially in patients on high-dose or long-term therapy [≥1 year]).</p></div>
<div class="block pha drugH1Div" id="F166935"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Proton pump inhibitor suppresses gastric acid secretion by inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. Esomeprazole is the S-isomer of omeprazole.</p></div>
<div class="block phk drugH1Div" id="F166950"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 16 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C19 primarily and (to a lesser extent) via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 64% after a single 40 mg dose; 90% with repeat 40 mg once-daily dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 0.93 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: 0.42 to 0.74 hours (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 0.73 to 0.88 hours (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: 0.82 to 1.22 hours (Li 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~1 to 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Median: 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: 1.33 to 1.44 hours (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 1.75 to 1.79 hours (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: 1.96 to 2.04 hours (Li 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%, primarily as inactive metabolites; &lt;1% as active drug); feces (20%).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance (with repeated dosing):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: 6 to 19.44 L/hour (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 7.84 to 9.22 L/hour (Zhao 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: 8.36 to 15.88 L/hour (Li 2006).</p></div>
<div class="block phksp drugH1Div" id="F51154057"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC was 2 to 3 times higher in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC and C<sub>max</sub> were increased by 25% and 18%, respectively, following administration of esomeprazole magnesium.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC and C<sub>max</sub> were 13% higher in women than men following administration of esomeprazole magnesium.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F166958"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Esural | Pumpinox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alzepral | Esomax | Esoprazol | Nexium | Sarmec | Sinulcus | Solugastril | Ultrex</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Durotiv | Esomeprazol 1a Pharma | Esomeprazol actavis | Esomeprazol Hexal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">24 Hour Once Daily Heartburn Relief - Pharmacy action | Apo esomeprazole | Apohealth esomeprazole heartburn relief | Blooms the chemist esomeprazole heartburn relief | Esomeprazole actavis | Esomeprazole amneal | Esomeprazole Apotex | Esomeprazole gh | Esomeprazole gxp | Esomeprazole mylan | Esomeprazole sandoz | Esopreze | Guardium Acid Reflux Relief | Mepreze | Nexazole | Nexium | Nexium 24hr | Nexole | Noumed esomeprazole | Noxicid | Pharmacor esomeprazole | Trust nexcid | Zanzole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alton | Curacid | Ema | Emep | Emo | Erazole | Esmosec | Eso | Esocon | Esogap | Esolok | Esomep | Esomiloc | Esomups | Esonam | Esonix | Esonix m | Esopin | Esopra | Esoral | Esotac | Esotem | Esotid | Esotor | Espram | Exilok | Exium | Exome | Ezoom | Gaspro | Maxpro | Nexe | Nexpro | Nexum | Nexum mups | Onepro | Opton | Preso | Progut | Pronex | Sergel | Xelpro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Esobax | Esomeprazol renantos | Esomeprazole eg | Nexiam</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Es ulcizone | Esomed | Esomep | Inexium | Inigast | Raciper | Ulzocer | Yesom</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Esmerol | Gastrocid eso | Helides | Nexium | Nexopral | Ormus | Refluxend</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Esio | Esogastro | Esomeprazol magnesio | Ezobloc | Mezolium | Nexium</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol axapharm | Esomeprazol mepha | Esomeprazol mut sandoz | Esomeprazol n spirig hc | Esomeprazol sandoz | Esomeprazol Spirig | Esoprazol actavis | Nexium mups</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Es ulcizone | Esac | Esocon | Esomecro | Esomed | Esta | Inigast | Raciper | Ulzocer | Yesom</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cor | Cronopep | Emezol | Epral | Esio | Esozole | Gastrezol | Neoren</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai su ping | Bang ka xin | Lai mei shu | Nexium</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acidprazol | Cronopep | Dumepraz | Esomax | Esomed | Esomeprazol | Esomeprazol mk | Esomezol | Esomine | Esopront | Esotlen | Esoz | Expozole | Ezolium | Garmisch esomax | Gastridina | Gastroter nf | Gastrumprazol | Gazilex | Genecazol | Melconar | Nedox | Nersedal | Nexium | Nexium mups | Pamezone | Prazbal | Prazomerol | Presomid | Sitomakil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Nexium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol abz | Esomeprazol ct | Esomeprazol puren | Esomeprazol ratiopharm | Esomeprazol sandoz | Esomeprazol tad | Esomeprazol teva | Nexium | Nexium mups</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Esopral</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Carbum | Esomep | Esomeprazol | Esomeprazol mk | Esopral aglf | Esoz | Ezolium | Farprazol | Felprazol | Finitacid | Gastrofran | Iberprazol | Nexium | Qualium</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Axasole | Deroprax | E Liprot | Esomeprazol | Esomezz | Esonix | Esoz | Ezolium | Proteus | Ulceran | Ulcium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eradizol | Escadra | Nexium</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Biorazo | Esmatac | Esmopump | Esmorap | Eso protocol | Esogerdazole | Esomelodan | Esomepex | Esopiroxan | Nexicure | Neximash | Nixprazole | Serioprazole</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Axiago | Esomeprazol Bexal | Esomeprazol cinfa | Esomeprazol Mabo | Esomeprazol mundogen | Esomeprazol pensa | Esomeprazol sandoz | Esomeprazol stada | Esomeprazol Tarbis | Esomeprazol vir</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol | Esomeprazole | Esomeprazole Apotex | Esomeprazole sandoz | Esotor | Esoz | Esozole | Nexium | Pumpinox | Raciper | Somezole</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Acidal | Esomeprazol actavis | Esomeprazol Navamedic | Esomeprazol orion | Esomeprazol ratiopharm | Esomeprazol sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazole Arrow | Esomeprazole Dci | Esomeprazole eg | Esomeprazole ranbaxy | Esomeprazole sun | Inexium</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Guardium acid reflux control | Heartburn and Acid Reflux Control | Nexium | Nexium control</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Elco free | Esactive | Nexium | Prazonex</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Esomag</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo esomeprazole | Emanera | Esomeprazole sandoz | Esopel | Nexium | Prosome | Stadnex | Ventra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Esomeprazol PharmaS | Nexium | Seval</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Emozul control | Esomeprazol actavis | Esomeprazol sandoz | Nexium | Raciper</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Esola | Esomeprazole | Nexium | S omevell</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazole | Nexium</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Nexium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">4ph | Ceso | Coloncid | Ecorest | Esaktive | Esaktive Fast | Escid | Esiloc | Esium | Eslo | Esmopil | Esmozole | Esobiz | Esobrick | Esocid | Esocor | Esodin 40 | Esodoc | Esofag | Esofence | Esofine | Esofit | Esogress | Esokem | Esolembic | Esolyst | Esomac | Esomcure | Esomecid | Esomefol | Esomez | Esomezole | Esontia | Esopaz | Esopel | Esoper | Esoprz | Esorest | Esoser | Esotab | Esotrax | Esotrend | Esoz | Espearl | Espra | Estab | Esvoz | Eszole | Eyz | Izra | Lupisoz | Mexium | Nexium | Nexpro | Nexpro fast | Nuloc | Odepraz | Omoye es | Oncarbi | Opec | Oskar-s | Pirazole S | Prevzole | Raciper | S ppi | Septor | Somifiz | Sompraz | Tom FT | YeeS | Zolgas | Zosa | Zosec-s</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abigerd | Axagon | Collezoes | Esodor | Esomenar | Esomeprazolo cipla | Esomeprazolo eg | Esomeprazolo Git | Esomeprazolo ranbaxy | Esopral | Lucen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Esomep | Pumpinox</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cidopraz | E zole | Es omecos | Esma | Esocip | Esofag | Esofast | Esoflux | Esofred | Esomac | Esome | Esomega | Esomep | Esomepram | Esomezol | Esonium | Esopra | Esopraz | Esoral | Esose | Esostar | Esotid | Espra | Esta | Exium | Ezo | Gastro iv | Gastrotab | Grasozole | Izra | Maxezole | Nexend | Nexiole | Nexmezole | Nexpro | Prazonac | Protas | Rayzium | Sompraz | Stulcer | Yesom | Zomep es</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anaprazole | Anticium | Busomezole | Cj esomeprazole | Daewoongbio esomeprazole | Dso | Emazole | Emepra | Enexium | Entixium | Epium | Epramine | Eprazole | Esbet | Escorten | Esme | Esmepzol | Esmezole | Esnezol | Eso | Eso one | Esocid | Esodole | Esogard | Esogen | Esomach | Esomax | Esome | Esomecan | Esomedi | Esomekhan | Esomel | Esomepra | Esomera | Esometwo | Esomezol | Esomezol dr | Esonel | Esonol | Esopazole | Esopiem | Esopirazole | Esopm | Esopra | Esoprazole | Esoprezole | Esora | Esorazol | Esorium | Esosium | Esotec | Esotech ddr | Esotizol | Esoton | Esozol | Esozole | Espra | Esprazole | Esprizole | Esprole | Esrazole | Esrozole | Eswonamp | Esxium | Eszol | Exi r | Exipium | Exmezole | Exorazol | Exoxium | Exozole | Ganaxium | H prazole | Hanxium | Huvimezole | Ildong esomeprazole magnesium trihydrate | Inno.n esomeprazole | Koprazole | Lesomezole | Negsomera | Nektra | Nelpra | Nemeol | Neomezole | New esopra | Nexa v | Nexera | Nexialdi | Nexiel | Nexien | Nexierd | Neximezole | Nexiome | Nexion | Nexipra | Nexirium | Nexium | Nexokhan | Nexome | Nexon | Nexopra | Nexorazole | Nexpa | Nexpesol | Nexpezole | Nexpium | Nexprazole | Nexrazole | Nexypra | Nexzole | Ome s | Omena | Omeple | Omepro s | Omes | Ometon s | Ometone s | Omp s | Omps | Pharma esomeprazole | Rp eso | S empra | Samsung esomeprazole | Sinesome | Som | Somed | Tdpra | Unixium | Vangelis | Weprazole | Wimezole | Yesome | Yoosmezole ddr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Esomelodan | Esomep | Esural</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Esomep | Metapro | Nexium | Pumpinox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Escadra | Nexium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol sandoz | Esomeprazole eg | Nexiam</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gastridex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Esac | Ineso | Inexium | Raciper</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amably 24 hrs | Doxacor | Esomeprazol | Goflaxcol | Lanzoker | Mubiprol | Nexium | Nexium 24hr | Nexium mups | Sansflu | Tronium</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axiago | Esomac | Esoz | Nexium</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Esocon | Esomega | Esomeprazole | Esomeprazole sandoz | Esorest | Esoswift | Espacid | Jubium | Stulcer</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol pch | Esomeprazol sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol actavis | Esomeprazol pensa | Esomeprazol sandoz | Esopral | Nexium</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Axasole | Bonazol | Eso frenacid | Esomeprazol | Esopran | Esoprazole | Esoswift | Ezolium | Neopral | Protium | Raciper | Sak | Sompraz | Ulceran</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Esofag | Esoflux | Esomap | Esomebloc | Esomep | Esometor | Espazol | Izol | Nexmezole | Nexopraz | Nexpro | Ppi max | Preprazole | S gastriloc | Xsom</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acidease | Acidof | Albomep | Aldis | Anvitoff | Artek | Asector | Axigo | Axio | Axiom | Benprol | Brf | Brince | E Zol | Emazol | Epim | Esasia | Esdor | Eseft | Esiam | Esmocid | Esmond | Esoact | Esobert | Esobest | Esobin | Esofine | Esokan | Esold | Esolone | Esolong | Esopep | Esophag | Esoproto | Esoproz | Esorant | Esorest | Esorok | Esosol | Esotek | Esox | Esozet | Espharm | Espo | Espra | Essogene | Esteem | Evixa | Exporam | Exzium | Ezorain | Ezotab | Eztomac | Fasteso | Gem ton | Gesteze | Gutsy | Indazole | Jadore | Jenrex | Limazat | Mepraz | Mepzole | Monepra | Myeso | Navix | Nexpro | Nexum | Pep ease | Pepkap | Pepmit | Pepnor | Pepso | Petra | Prabest | Prop ac | Protx | Reciper | Relaxul | Remep | Renzole | Rexium | S Om | S-mepra | Sabizole | Smaz | Smep | Solcer | Somep | Somrit | Staesso | Therasome | Tripra | V es | Wesom | Zune</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Escid control | Helides | Nexium | Stomezul | Texibax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Esomep ezs | Nexium 24hr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol | Esomeprazol Azevedos | Esomeprazol emozul | Esomeprazol gp | Nexium</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Antiul | Buntal | Esomeprazol dasanti | Gasent | Inflamace | Mofin | Peutic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Esolab | Esomep | Esural | Kenzoprazole | Nexium | Nexium IV | Nexpro | Pumpinox | Zynex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol sandoz | Esomeprazol Terapia | Esomeprazol teva | Esomeprazol Torrent</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Emezol | Esomeprazole | Esomeprazole canon | Esomeprazole sz | Esomeprazole vial | Neo Zext | Pemozar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo esomeprazole | Emanera | Esomep | Esomeprazole | Esural</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol actavis | Esomeprazol orion | Esomeprazol pensa | Nexium | Nexium control</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Esoz | Jubium | Nexium</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nexium | Nilar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Nexium | Remesolin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Esocalm</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nexomep | Nexstep</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amipasole | Apo esomeprazole | Esomeprazol sandoz</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Esonexa | Ezolong | Ezox | Nexium | Nexpro</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Esmo | Esomac | Esomelodan | Esorest | Esoriv | Esoz | Ezo | Nexmezole | Nexpro | Zesoz</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Esomeprazol | Esopral | Esoprazol | Medezol | Nexium</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Esomac | Esomeprazol | Esosan | Gletop | Nexplus</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">A.t esomeprazol | Ameprazol | Capesto | Esalep | Esapbe | Esomeptab | Esoragim | Estor | Gasgood | Goldesome | Jiracek | Leninrazol | Nozaxen | Pramebig | Prasocare | Prasogem | Prazopro | Revole | SaVi esomeprazole | Somexwell | Sopezid | Sunpranza | Topenti</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Emanera | Esotab | Fluxtrin | Nectizole | Nesopram | Nexiflux | Nexilok | Nexipraz | Nexmezol | Nexomep | Trustan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ceso | Esaktive | Esoz | Nexium | Nexpro | Raciper</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Esoz | Nexpro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22697020">
<a name="22697020"></a>Abdul Razzak E, Tomás M, Tornero P, Herrero T. Nine cases of allergy to omeprazole. <i>J Investig Allergol Clin Immunol</i>. 2012;22(3):228-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22697020/pubmed" id="22697020" target="_blank">22697020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26621819">
<a name="26621819"></a>Abdul-Hussein M, Freeman J, Castell D. Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. <i>Pharmacotherapy</i>. 2015;35(12):1124-1129. doi:10.1002/phar.1665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26621819/pubmed" id="26621819" target="_blank">26621819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al, “ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,” <i>Circulation</i>, 2010, 122(24):2619-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010681">
<a name="23010681"></a>Abraham NS. Proton pump inhibitors: potential adverse effects. <i>Curr Opin Gastroenterol</i>. 2012;28(6):615-620. doi:10.1097/MOG.0b013e328358d5b9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23010681/pubmed" id="23010681" target="_blank">23010681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24507954">
<a name="24507954"></a>Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. <i>Ann Epidemiol</i>. 2014;24(4):286-290. doi:10.1016/j.annepidem.2014.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24507954/pubmed" id="24507954" target="_blank">24507954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27398293">
<a name="27398293"></a>Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. <i>Drugs Real World Outcomes</i>. 2016;3(2):145-154. doi:10.1007/s40801-016-0067-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27398293/pubmed" id="27398293" target="_blank">27398293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35508989">
<a name="35508989"></a>Ali RAR, Hassan J, Egan LJ. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. <i>BMC Gastroenterol</i>. 2022;22(1):219. doi:10.1186/s12876-022-02287-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35508989/pubmed" id="35508989" target="_blank">35508989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32607016">
<a name="32607016"></a>Almansouri AY, Alzahrani ZA. A case of rhupus with Rowell syndrome. <i>Open Access Rheumatol</i>. 2020;12:91-96. doi:10.2147/OARRR.S255790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32607016/pubmed" id="32607016" target="_blank">32607016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23548825">
<a name="23548825"></a>Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. <i>Dermatology</i>. 2013;226(2):119-123. doi:10.1159/000346694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23548825/pubmed" id="23548825" target="_blank">23548825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22102545">
<a name="22102545"></a>Anderka M, Mitchell AA, Louik C, et al, "Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects," <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22102545/pubmed" id="22102545" target="_blank">22102545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11510629">
<a name="11510629"></a>Andersson T, Hasan-Alin M, Hasselgren G, et al, “Drug Interactions Studies With Esomeprazole, the (S)-Isomer of Omeprazole,” <i>Clin Pharmacokinet</i>, 2001, 40(7):523-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/11510629/pubmed" id="11510629" target="_blank">11510629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33751184">
<a name="33751184"></a>Aydın Yoldemir Ş, Zeren Ozturk G, Akarsu M, Ozcan M. Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?. <i>Wien Klin Wochenschr</i>. 2022;134(3-4):104-109. doi:10.1007/s00508-021-01834-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33751184/pubmed" id="33751184" target="_blank">33751184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26209167">
<a name="26209167"></a>Bahtiri E, Islami H, Hoxha R, et al. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. <i>J Bone Miner Metab</i>. 2016;34(5):571-579. doi:10.1007/s00774-015-0699-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26209167/pubmed" id="26209167" target="_blank">26209167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31634917">
<a name="31634917"></a>Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. <i>Ann Intern Med</i>. 2019;171(11):805‐822. doi:10.7326/M19-1795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31634917/pubmed" id="31634917" target="_blank">31634917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20083829">
<a name="20083829"></a>Barkun AN, Bardou M, Kuipers EJ, et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. <i>Ann Intern Med</i>. 2010;152(2):101-113. doi:10.7326/0003-4819-152-2-201001190-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20083829/pubmed" id="20083829" target="_blank">20083829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080034">
<a name="27080034"></a>Bayerdörffer E, Bigard MA, Weiss W, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. <i>BMC Gastroenterol</i>. 2016;16:48. doi:10.1186/s12876-016-0448-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27080034/pubmed" id="27080034" target="_blank">27080034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058396">
<a name="30058396"></a>Benito-Garcia F, Chambel M, Morais-Almeida M. Anaphylaxis due to proton pump inhibitors: current understanding and important clinical considerations. <i>Expert Rev Clin Immunol</i>. 2018;14(8):653-656. doi:10.1080/1744666X.2018.1505504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30058396/pubmed" id="30058396" target="_blank">30058396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24629073">
<a name="24629073"></a>Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? <i>Nephrology (Carlton)</i>. 2014;19(6):359-365. doi:10.1111/nep.12226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24629073/pubmed" id="24629073" target="_blank">24629073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28401712">
<a name="28401712"></a>Bhana A, Waters MJ, Fazal MW, Kimber T. Pantoprazole-induced hypomagnesaemia causing cerebellar syndrome and seizures. <i>Intern Med J</i>. 2017;47(4):467-468. doi:10.1111/imj.13388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28401712/pubmed" id="28401712" target="_blank">28401712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16944963">
<a name="16944963"></a>Blume H, Donath F, Warnke A, et al, “Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors,” <i>Drug Saf</i>, 2006, 29(9): 769-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16944963/pubmed" id="16944963" target="_blank">16944963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonis.1">
<a name="Bonis.1"></a>Bonis PAL, Gupta SK. Treatment of eosinophilic esophagitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267357">
<a name="24267357"></a>Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. <i>Ann Allergy Asthma Immunol</i>. 2013;111(6):452-457. doi:10.1016/j.anai.2013.08.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24267357/pubmed" id="24267357" target="_blank">24267357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24751668">
<a name="24751668"></a>Bourneau-Martin D, Leclech C, Jamet A, et al. Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Eur J Dermatol</i>. 2014;24(3):413-415. doi:10.1684/ejd.2014.2343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24751668/pubmed" id="24751668" target="_blank">24751668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17711546">
<a name="17711546"></a>Caboni S, Gunera-Saad N, Ktiouet-Abassi S, Berard F, Nicolas JF. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. <i>Allergy</i>. 2007;62(11):1342-1343. doi:10.1111/j.1398-9995.2007.01428.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17711546/pubmed" id="17711546" target="_blank">17711546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820. doi:10.1542/peds.2005-1655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28842261">
<a name="28842261"></a>Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of <i>Clostridium difficile</i> infection. <i>J Hosp Infect</i>. 2018;98(1):4-13. doi:10.1016/j.jhin.2017.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28842261/pubmed" id="28842261" target="_blank">28842261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675130">
<a name="30675130"></a>Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. <i>Clin Mol Allergy</i>. 2019;17:1. doi:10.1186/s12948-019-0104-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30675130/pubmed" id="30675130" target="_blank">30675130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26108134">
<a name="26108134"></a>Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. <i>Ren Fail</i>. 2015;37(7):1237-1241. doi:10.3109/0886022X.2015.1057800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26108134/pubmed" id="26108134" target="_blank">26108134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD and Wong B, “American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,” <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36626173">
<a name="36626173"></a>Choi A, Noh Y, Jeong HE, et al. Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations. <i>JAMA Netw Open</i>. 2023;6(1):e2250366. doi:10.1001/jamanetworkopen.2022.50366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/36626173/pubmed" id="36626173" target="_blank">36626173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23134998">
<a name="23134998"></a>Chularojanamontri L, Jiamton S, Manapajon A, et al. Cutaneous reactions to proton pump inhibitors: a case-control study. <i>J Drugs Dermatol</i>. 2012;11(10):e43-e47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23134998/pubmed" id="23134998" target="_blank">23134998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10417548">
<a name="10417548"></a>Cockayne SE, Glet RJ, Gawkrodger DJ, et al, “Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,” <i>Br J Dermatol</i>,1999, 141(1):173-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10417548/pubmed" id="10417548" target="_blank">10417548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25752807">
<a name="25752807"></a>Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. <i>Br J Clin Pharmacol</i>. 2015;80(2):200-208. doi:10.1111/bcp.12619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25752807/pubmed" id="25752807" target="_blank">25752807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16440530">
<a name="16440530"></a>Confino-Cohen R, Goldberg A. Anaphylaxis to omeprazole: diagnosis and desensitization protocol. <i>Ann Allergy Asthma Immunol</i>. 2006;96(1):33-36. doi:10.1016/S1081-1206(10)61037-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16440530/pubmed" id="16440530" target="_blank">16440530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20353792">
<a name="20353792"></a>Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. <i>Gastroenterology</i>. 2010;139(1):93-101. doi:10.1053/j.gastro.2010.03.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20353792/pubmed" id="20353792" target="_blank">20353792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31378636">
<a name="31378636"></a>Corley DA. Safety and complications of long-term proton pump inhibitor therapy: getting closer to the truth. <i>Gastroenterology</i>. 2019;157(3):604-607. doi:10.1053/j.gastro.2019.07.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31378636/pubmed" id="31378636" target="_blank">31378636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18221401">
<a name="18221401"></a>Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. <i>Clin Endocrinol (Oxf)</i>. 2008;69(2):338-341. doi:10.1111/j.1365-2265.2008.03194.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18221401/pubmed" id="18221401" target="_blank">18221401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18176768">
<a name="18176768"></a>Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. <i>Acta Derm Venereol</i>. 2008;88(1):87-89. doi:10.2340/00015555-0335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18176768/pubmed" id="18176768" target="_blank">18176768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23800403">
<a name="23800403"></a>Davidson G, Wenzl TG, Thomson M, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. <i>J Pediatr</i>. 2013;163(3):692-698.e1-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23800403/pubmed" id="23800403" target="_blank">23800403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23034135">
<a name="23034135"></a>de Jager CP, Wever PC, Gemen EF, et al, “Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,” <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23034135/pubmed" id="23034135" target="_blank">23034135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31817776">
<a name="31817776"></a>Douwes RM, Gomes-Neto AW, Schutten JC, et al. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. <i>J Clin Med</i>. 2019;8(12):2162. doi:10.3390/jcm8122162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31817776/pubmed" id="31817776" target="_blank">31817776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36194028">
<a name="36194028"></a>Dunbar K, Yadlapati R, Konda V. Heartburn, nausea, and vomiting during pregnancy. <i>Am J Gastroenterol</i>. 2022;117(10S):10-15. doi:10.14309/ajg.0000000000001958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/36194028/pubmed" id="36194028" target="_blank">36194028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22240865">
<a name="22240865"></a>Dury S, Nardi J, Gozalo C, Lebargy F, Deslee G. Agranulocytosis induced by proton pump inhibitors. <i>J Clin Gastroenterol</i>. 2012;46(10):859. doi:10.1097/MCG.0b013e318236f18a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22240865/pubmed" id="22240865" target="_blank">22240865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC; Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. <i>Pediatrics</i>. Published online July 2, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22314213">
<a name="22314213"></a>Erichsen R, Mikkelsen E, Pedersen L, et al, "Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring," <i>Am J Ther</i>, 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22314213/pubmed" id="22314213" target="_blank">22314213</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Esomeprazole Strontium [prescribing information]. Ripley, MS: Sterling Knight Pharmaceuticals LLC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22800870">
<a name="22800870"></a>Famularo G, Minisola G, Bravi MC, Colucci P, Gasbarrone L. Tetany, hypomagnesemia, and proton-pump inhibitors. <i>Am J Med</i>. 2012;125(10):e7-e8. doi:10.1016/j.amjmed.2012.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22800870/pubmed" id="22800870" target="_blank">22800870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17505990">
<a name="17505990"></a>Fändriks L, Lönroth H, Pettersson A, Vakil N. Can famotidine and omeprazole be combined on a once-daily basis? <i>Scand J Gastroenterol</i>. 2007;42(6):689-694. doi:10.1080/00365520601026665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17505990/pubmed" id="17505990" target="_blank">17505990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fass.2019">
<a name="Fass.2019"></a>Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Food and Drug Administration. Updated August 4, 2017. Accessed May 3, 2023. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16240222">
<a name="16240222"></a>Flick AL. Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium). <i>Dig Dis Sci</i>. 2005;50(11):2100-2102. doi:10.1007/s10620-005-3014-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16240222/pubmed" id="16240222" target="_blank">16240222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32092686">
<a name="32092686"></a>Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, et al. Molecular pathways driving omeprazole nephrotoxicity. <i>Redox Biol</i>. 2020;32:101464. doi:10.1016/j.redox.2020.101464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32092686/pubmed" id="32092686" target="_blank">32092686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25986385">
<a name="25986385"></a>Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. <i>Osteoporos Int</i>. 2015;26(10):2501-2507. doi:10.1007/s00198-015-3168-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25986385/pubmed" id="25986385" target="_blank">25986385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35599445">
<a name="35599445"></a>Gebreyesus MS, Decloedt EH, Cluver CA, et al. Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia. Br J Clin Pharmacol. 2022;88(10):4639-4645. doi:10.1111/bcp.15416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35599445/pubmed" id="35599445" target="_blank">35599445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16630752">
<a name="16630752"></a>Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. <i>Clin Gastroenterol Hepatol</i>. 2006;4(5):597-604. doi:10.1016/j.cgh.2005.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16630752/pubmed" id="16630752" target="_blank">16630752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15748135">
<a name="15748135"></a>Geevasinga N, Kairaitis L, Rangan GK, Coleman PL. Acute interstitial nephritis secondary to esomeprazole. <i>Med J Aust</i>. 2005;182(5):235-236. doi:10.5694/j.1326-5377.2005.tb06675.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/15748135/pubmed" id="15748135" target="_blank">15748135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894652">
<a name="17894652"></a>Goldstein JL, Johanson JF, Hawkey CJ, et al, “Clinical Trial: Healing of NSAID-Associated Gastric Ulcers in Patients Continuing NSAID Therapy – A Randomized Study Comparing Ranitidine With Esomeprazole,” <i>Aliment Pharmacol Ther</i>, 2007, 26(8):1101-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17894652/pubmed" id="17894652" target="_blank">17894652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33567467">
<a name="33567467"></a>Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. <i>Endoscopy</i>. 2021;53(3):300-332. doi:10.1055/a-1369-5274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33567467/pubmed" id="33567467" target="_blank">33567467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15741426">
<a name="15741426"></a>Grattagliano I, Portincasa P, Mastronardi M, Palmieri VO, Palasciano G. Esomeprazole-induced central fever with severe myalgia. <i>Ann Pharmacother</i>. 2005;39(4):757-760. doi:10.1345/aph.1E377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/15741426/pubmed" id="15741426" target="_blank">15741426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458083">
<a name="20458083"></a>Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. <i>Arch Intern Med</i>. 2010;170(9):765-771. doi:10.1001/archinternmed.2010.94<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20458083/pubmed" id="20458083" target="_blank">20458083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29872353">
<a name="29872353"></a>Gupta PP, Bhandari R, Mishra DR, et al. Anaphylactic reactions due to pantoprazole: case report of two cases. <i>Int Med Case Rep J</i>. 2018;11:125-127. doi:10.2147/IMCRJ.S153099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29872353/pubmed" id="29872353" target="_blank">29872353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639541">
<a name="32639541"></a>Hall EL, Peravali R, Patel TS. Omeprazole-induced subacute cutaneous lupus erythematosus. <i>JAMA Dermatol</i>. 2020;156(9):1013. doi:10.1001/jamadermatol.2020.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32639541/pubmed" id="32639541" target="_blank">32639541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30445008">
<a name="30445008"></a>Hansen KE, Nieves JW, Nudurupati S, Metz DC, Perez MC. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. <i>Gastroenterology</i>. 2019;156(4):926-934.e6. doi:10.1053/j.gastro.2018.11.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30445008/pubmed" id="30445008" target="_blank">30445008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635502">
<a name="17635502"></a>Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. <i>Br J Clin Pharmacol</i>. 2007;64(6):819-823. doi:10.1111/j.1365-2125.2007.02927.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17635502/pubmed" id="17635502" target="_blank">17635502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32359562">
<a name="32359562"></a>Hirano I, Chan ES, Rank MA, et al; AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32359562/pubmed" id="32359562" target="_blank">32359562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27134114">
<a name="27134114"></a>Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. <i>Allergol Int</i>. 2016;65(4):432-438. doi:10.1016/j.alit.2016.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27134114/pubmed" id="27134114" target="_blank">27134114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458086">
<a name="20458086"></a>Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial <i>Clostridium difficile</i> infection. <i>Arch Intern Med</i>. 2010;170(9):784-790. doi:10.1001/archinternmed.2010.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20458086/pubmed" id="20458086" target="_blank">20458086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34889253">
<a name="34889253"></a>Hsieh HH, Wu TY, Chen CH, Hour MJ. Cost-effectiveness and clinical outcomes of intermittent/continuous proton pump inhibitors infusion in high bleeding risk of ulcers: a retrospective observational cohort study. <i>Medicine (Baltimore).</i> 2021;100(49):e28064. doi:10.1097/MD.0000000000028064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/34889253/pubmed" id="34889253" target="_blank">34889253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25245625">
<a name="25245625"></a>Hsu PI, Lu CL, Wu DC, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. <i>Clin Gastroenterol Hepatol</i>. 2015;13(5):859.e1-866.e1. doi:10.1016/j.cgh.2014.09.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25245625/pubmed" id="25245625" target="_blank">25245625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36012913">
<a name="36012913"></a>Hussain S, Singh A, Antony B, et al. Proton pump inhibitors use and risk of preeclampsia: a meta- analysis. <i>J Clin Med</i>. 2022;11(16):4675. doi:10.3390/jcm11164675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/36012913/pubmed" id="36012913" target="_blank">36012913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17059515">
<a name="17059515"></a>Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. <i>Aliment Pharmacol Ther</i>. 2006;24(9):1341-1348. doi:10.1111/j.1365-2036.2006.03127.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17059515/pubmed" id="17059515" target="_blank">17059515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27442680">
<a name="27442680"></a>Jeon DH, Kim Y, Kim MJ, et al. Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: a case report. <i>Medicine (Baltimore)</i>. 2016;95(29):e4313. doi:10.1097/MD.0000000000004313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27442680/pubmed" id="27442680" target="_blank">27442680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541262">
<a name="28541262"></a>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). <i>J Pediatr Gastroenterol Nutr</i>. 2017;64(6):991-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28541262/pubmed" id="28541262" target="_blank">28541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kahrilas.2021">
<a name="Kahrilas.2021"></a>Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11012468">
<a name="11012468"></a>Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. <i>Aliment Pharmacol Ther</i>. 2000;14(10):1249-1258. doi:10.1046/j.1365-2036.2000.00856.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/11012468/pubmed" id="11012468" target="_blank">11012468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, “American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,” <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34995368">
<a name="34995368"></a>Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. <i>Cochrane Database Syst Rev.</i> 2022;1(1):CD005415. doi:10.1002/14651858.CD005415.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/34995368/pubmed" id="34995368" target="_blank">34995368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659167">
<a name="24659167"></a>Kara M, Tanoglu A, Kutlu A, Sirkeci O, Kekilli M. Esomeprazole: a safe alternative to lansoprazole allergy? <i>Iran J Allergy Asthma Immunol</i>. 2014;13(4):296-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24659167/pubmed" id="24659167" target="_blank">24659167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21470217">
<a name="21470217"></a>Kardaun SH, Tupker RA. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole. <i>Int J Dermatol</i>. 2012;51(9):1134-1137. doi:10.1111/j.1365-4632.2010.04689.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21470217/pubmed" id="21470217" target="_blank">21470217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34410975">
<a name="34410975"></a>Kato K, Mizuno T, Koseki T, et al. Concomitant proton pump inhibitors and immune checkpoint inhibitors increase nephritis frequency. <i>In Vivo</i>. 2021;35(5):2831-2840. doi:10.21873/invivo.12570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/34410975/pubmed" id="34410975" target="_blank">34410975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35198470">
<a name="35198470"></a>Kaur S, Singla P, Kaur S, Kansal A, Bansal A, Singh A. Proton pump inhibitor induced subacute cutaneous lupus erythematosus: a case series of 7 patients and brief review of literature. <i>Indian Dermatol Online J</i>. 2022;13(1):64-72. doi:10.4103/idoj.idoj_237_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35198470/pubmed" id="35198470" target="_blank">35198470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17014584">
<a name="17014584"></a>Keyvani L, Murthy S, Leeson S, Targownik LE. Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. <i>Aliment Pharmacol Ther.</i> 2006;24(8):1247-1255. doi:10.1111/j.1365-2036.2006.03115.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17014584/pubmed" id="17014584" target="_blank">17014584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767318">
<a name="29767318"></a>Kim J, Blackett JW, Jodorkovsky D. Strategies for effective discontinuation of proton pump inhibitors. <i>Curr Gastroenterol Rep</i>. 2018;20(6):27. doi: 10.1007/s11894-018-0632-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29767318/pubmed" id="29767318" target="_blank">29767318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109611">
<a name="23109611"></a>Klassen S, Krepinsky JC, Prebtani AP. Pantoprazole-induced acute interstitial nephritis. <i>CMAJ</i>. 2013;185(1):56-59. doi:10.1503/cmaj.120954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23109611/pubmed" id="23109611" target="_blank">23109611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32718584">
<a name="32718584"></a>Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. <i>Therapie</i>. 2021;76(1):13-21. doi:10.1016/j.therap.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32718584/pubmed" id="32718584" target="_blank">32718584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18614750">
<a name="18614750"></a>Kupiec TC, Aloumanis V, Ben M, et al, “Physical and Chemical Stability of Esomeprazole Sodium Solutions,” <i>Ann Pharmacother</i>, 2008, 42(9):1247-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18614750/pubmed" id="18614750" target="_blank">18614750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16225489">
<a name="16225489"></a>Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. <i>Aliment Pharmacol Ther</i>. 2005;22(9):803-811. doi:10.1111/j.1365-2036.2005.02643.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16225489/pubmed" id="16225489" target="_blank">16225489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21626263">
<a name="21626263"></a>Lai HC, Hsu SW, Lu CH, et al. Anaphylaxis to pantoprazole during general anesthesia. <i>J Anesth</i>. 2011;25(4):606-608. doi:10.1007/s00540-011-1148-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21626263/pubmed" id="21626263" target="_blank">21626263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22310222">
<a name="22310222"></a>Laine L, Jensen DM. Management of patients with ulcer bleeding. <i>Am J Gastroenterol</i>. 2012;107(3):345-360. doi:10.1038/ajg.2011.480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22310222/pubmed" id="22310222" target="_blank">22310222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2442. doi:10.1001/jama.2013.280490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240698">
<a name="19240698"></a>Lanza FL, Chan FK, and Quigley EM, “Guidelines for Prevention of NSAID-Related Ulcer Complications,” <i>Am J Gastroenterol</i>, 2009, 140(3):728-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19240698/pubmed" id="19240698" target="_blank">19240698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32677040">
<a name="32677040"></a>Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al; EUREOS EoE CONNECT research group. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Aliment Pharmacol Ther</i>. 2020;52(5):798-807. doi:10.1111/apt.15957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32677040/pubmed" id="32677040" target="_blank">32677040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17442905">
<a name="17442905"></a>Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. <i>N Engl J Med</i>. 2007;356(16):1631-1640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17442905/pubmed" id="17442905" target="_blank">17442905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10922420">
<a name="10922420"></a>Lau JY, Sung JJ, Lee KK, et al, “Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,” <i>N Engl J Med</i>, 2000, 343(5):310-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10922420/pubmed" id="10922420" target="_blank">10922420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26752337">
<a name="26752337"></a>Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26752337/pubmed" id="26752337" target="_blank">26752337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36142643">
<a name="36142643"></a>Lespessailles E, Toumi H. Proton pump inhibitors and bone health: an update narrative review. <i>Int J Mol Sci</i>. 2022;23(18):10733. doi:10.3390/ijms231810733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/36142643/pubmed" id="36142643" target="_blank">36142643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35135340">
<a name="35135340"></a>Leung T, Kedzior S, Moore K, Bierman J, Coralic Z. Intermittent versus continuous infusion dosing of intravenous proton pump inhibitors for upper gastrointestinal bleeding.<i> Ann Pharmacother.</i> 2022;56(10):1127-1132. doi:10.1177/10600280211073936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35135340/pubmed" id="35135340" target="_blank">35135340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16750456">
<a name="16750456"></a>Li J, Zhao J, Hamer-Maansson JE, et al, "Pharmacokinetic Properties of Esomeprazole in Adolescent Patients Aged 12 to 17 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study," <i>Clin Ther</i>, 2006, 28(3):419-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16750456/pubmed" id="16750456" target="_blank">16750456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33089794">
<a name="33089794"></a>Li PH. Skin testing for hypersensitivity and cross-reactivity between proton pump inhibitors. <i>Hong Kong Med J</i>. 2020;26(5):450.e1-450.e2. doi:10.12809/hkmj198267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33089794/pubmed" id="33089794" target="_blank">33089794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15258107">
<a name="15258107"></a>Li X-Q, Anderson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Disp</i>, 2004, 32(8):821-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/15258107/pubmed" id="15258107" target="_blank">15258107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA, and the Section on Gastroenterology, Hepatology, and Nutrition, "Gastroesophageal Reflux: Management Guidance for the Pediatrician," <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28658503">
<a name="28658503"></a>Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. <i>Allergy</i>. 2018;73(1):221-229. doi:10.1111/all.13235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28658503/pubmed" id="28658503" target="_blank">28658503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9437379">
<a name="9437379"></a>Lin HJ, Lo WC, Lee FY, et al, “A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy,” <i>Arch Intern Med</i>, 1998, 158(1):54-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/9437379/pubmed" id="9437379" target="_blank">9437379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32933772">
<a name="32933772"></a>Lin YT, Yang JC, Chu CY. Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. <i>Lung Cancer</i>. 2020;148:177-178. doi:10.1016/j.lungcan.2020.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32933772/pubmed" id="32933772" target="_blank">32933772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22646140">
<a name="22646140"></a>Liu N, Liu L, Zhang H, et al. Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. <i>J Gastroenterol Hepatol.</i> 2012;27(9):1473-1479. doi:10.1111/j.1440-1746.2012.07191.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22646140/pubmed" id="22646140" target="_blank">22646140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19274931">
<a name="19274931"></a>Lobera T, Navarro B, Del Pozo MD, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. <i>J Investig Allergol Clin Immunol</i>. 2009;19(1):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19274931/pubmed" id="19274931" target="_blank">19274931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247167">
<a name="26247167"></a>Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2016;14(1):13-22.e1. doi:10.1016/j.cgh.2015.07.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26247167/pubmed" id="26247167" target="_blank">26247167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058466">
<a name="32058466"></a>Lyu B, Jorgenson MR, Hansen KE, Djamali A, Astor BC. Proton pump inhibitors, but not H2-receptor antagonists, are associated with incident fractures among kidney transplant recipients. <i>Transplantation</i>. 2020;104(12):2609-2615. doi:10.1097/TP.0000000000003178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32058466/pubmed" id="32058466" target="_blank">32058466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33208878">
<a name="33208878"></a>Ma X, Huang L, Huang Z, et al. The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis. <i>Sci Rep</i>. 2020;10(1):20063. doi:10.1038/s41598-020-77245-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33208878/pubmed" id="33208878" target="_blank">33208878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20378675">
<a name="20378675"></a>Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. <i>QJM</i>. 2010;103(6):387-395. doi:10.1093/qjmed/hcq021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20378675/pubmed" id="20378675" target="_blank">20378675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175146">
<a name="31175146"></a>Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. <i>Pediatrics</i>. 2019;144(1):e20182625. doi:10.1542/peds.2018-2625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31175146/pubmed" id="31175146" target="_blank">31175146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31742205">
<a name="31742205"></a>Marconcini S, Giammarinaro E, Cosola S, Genovesi AM, Covani U. Mandibular osteonecrosis associated with antacid therapy (esomeprazole). <i>Eur J Case Rep Intern Med</i>. 2019;6(10):001279. doi:10.12890/2019_001279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31742205/pubmed" id="31742205" target="_blank">31742205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9582548">
<a name="9582548"></a>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. <i>Can J Gastroenterol</i>. 1998;12(3):225-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/9582548/pubmed" id="9582548" target="_blank">9582548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31152740">
<a name="31152740"></a>Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. <i>Gastroenterology</i>. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31152740/pubmed" id="31152740" target="_blank">31152740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24927897">
<a name="24927897"></a>Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. <i>Am J Kidney Dis</i>. 2014;64(4):558-566. doi:10.1053/j.ajkd.2014.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24927897/pubmed" id="24927897" target="_blank">24927897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30237993">
<a name="30237993"></a>Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. <i>J Bone Metab</i>. 2018;25(3):141-151. doi:10.11005/jbm.2018.25.3.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30237993/pubmed" id="30237993" target="_blank">30237993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]. Published September 3, 2014. Accessed May 3, 2023. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10772433">
<a name="10772433"></a>Natsch S, Vinks MH, Voogt AK, et al, “Anaphylactic Reactions to Proton-Pump Inhibitors,” <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10772433/pubmed" id="10772433" target="_blank">10772433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22122397">
<a name="22122397"></a>Negri AL, Valle EE. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. <i>Curr Drug Saf</i>. 2011;6(3):204-206. doi:10.2174/157488611797579320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22122397/pubmed" id="22122397" target="_blank">22122397</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nexium (esomeprazole magnesium) [prescribing information]. Wilmington, DE: AstraZeneca; March 2022.</div>
</li>
<li>
<div class="reference">
                  Nexium (esomeprazole magnesium) [prescribing information]. Wilmington, DE: AstraZeneca; July 2023.</div>
</li>
<li>
<div class="reference">
                  Nexium (esomeprazole magnesium) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexium.3">
<a name="Nexium.3"></a>Nexium 24HR (esomeprazole magnesium trihydrate) [prescribing information]. Madison, NJ: Pfizer; received September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexium.4">
<a name="Nexium.4"></a>Nexium 24HR Clear Minis (esomeprazole magnesium trihydrate) delayed-release capsules [prescribing information]. Madison, NJ: Pfizer; received September 2022.</div>
</li>
<li>
<div class="reference">
                  Nexium IV (esomeprazole sodium) [prescribing information]. Wilmington, DE: AstraZeneca; March 2022.</div>
</li>
<li>
<div class="reference">
                  Nexium IV (esomeprazole sodium) [prescribing information]. Wilmington, DE: AstraZeneca; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21143456">
<a name="21143456"></a>Ni N, Moeckel GW, Kumar C. Late-onset omeprazole-associated acute interstitial nephritis. <i>J Am Geriatr Soc</i>. 2010;58(12):2443-2444. doi:10.1111/j.1532-5415.2010.03194.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21143456/pubmed" id="21143456" target="_blank">21143456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19394048">
<a name="19394048"></a>Omari T, Lundborg P, Sandström M, et al, "Pharmacodynamics and Systemic Exposure of Esomeprazole in Preterm Infants and Term Neonates With Gastroesophageal Reflux Disease," <i>J Pediatr</i>, 2009, 155(2):222-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19394048/pubmed" id="19394048" target="_blank">19394048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23455632">
<a name="23455632"></a>Ozdil K, Kahraman R, Sahin A, et al. Bone density in proton pump inhibitors users: a prospective study. <i>Rheumatol Int</i>. 2013;33(9):2255-2260. doi:10.1007/s00296-013-2709-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23455632/pubmed" id="23455632" target="_blank">23455632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31187275">
<a name="31187275"></a>Park YH, Seong JM, Cho S, et al. Effects of proton pump inhibitor use on risk of <i>Clostridium difficile</i> infection: a hospital cohort study. <i>J Gastroenterol</i>. 2019;54(12):1052-1060. doi:10.1007/s00535-019-01598-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31187275/pubmed" id="31187275" target="_blank">31187275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26209527">
<a name="26209527"></a>Parks T, Ragland KL, Steiner MA, Subramony C, Bishop P, Nowicki M. Ménétrier mimicker complicating ulcerative colitis: proton-pump inhibitor-induced hyperplastic polyps. <i>J Pediatr</i>. 2015;167(3):776.e1. doi:10.1016/j.jpeds.2015.06.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26209527/pubmed" id="26209527" target="_blank">26209527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17083378">
<a name="17083378"></a>Paoluzi P, Iacopini F, Crispino P, et al, “2-Week Triple Therapy for <i>Helicobacter pylori</i> Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,” <i>Helicobacter</i>, 2006, 11(6):562-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17083378/pubmed" id="17083378" target="_blank">17083378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269915">
<a name="37269915"></a>Peron A, Ripoche E, Picot C, Ajiji P, Cucherat M, Cottin J. Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations. <i>Reprod Toxicol</i>. 2023;119:108419. doi:10.1016/j.reprotox.2023.108419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/37269915/pubmed" id="37269915" target="_blank">37269915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26939578">
<a name="26939578"></a>Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. <i>Aliment Pharmacol Ther</i>. 2016;43(9):985-993. doi:10.1111/apt.13576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26939578/pubmed" id="26939578" target="_blank">26939578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28325163">
<a name="28325163"></a>Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. <i>Epidemiol Infect</i>. 2017;145(8):1617-1623. doi:10.1017/S0950268817000528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28325163/pubmed" id="28325163" target="_blank">28325163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610598">
<a name="29610598"></a>Qorraj-Bytyqi H, Hoxha R, Sadiku S, et al. Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow up of 12 months. <i>Open Access Maced J Med Sci</i>. 2018;6(3):442-446. doi:10.3889/oamjms.2018.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29610598/pubmed" id="29610598" target="_blank">29610598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930865">
<a name="21930865"></a>Quasdorff M, Mertens J, Dinter J, Steffen HM. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. <i>Ann Intern Med</i>. 2011;155(6):405-407. doi:10.7326/0003-4819-155-6-201109200-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21930865/pubmed" id="21930865" target="_blank">21930865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30792587">
<a name="30792587"></a>Ribeiro RHT, Ribeiro FA, Silva RPM, Bortolini MJS, Garrote-Filho MDS, Penha-Silva N. Depression, hematologic parameters, and blood levels of vitamin B<sub>12</sub> in patients with laryngopharyngeal reflux under use of proton pump inhibitors. <i>Clin Med Insights Ear Nose Throat</i>. 2019;12:1179550619828683. doi:10.1177/1179550619828683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30792587/pubmed" id="30792587" target="_blank">30792587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30051945">
<a name="30051945"></a>Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse reactions: a case-population approach using a registry and a health care database. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(9):1042-1050. doi:10.1002/pds.4622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30051945/pubmed" id="30051945" target="_blank">30051945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25201154">
<a name="25201154"></a>Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. <i>JAMA Intern Med</i>. 2014;174(11):1755-1762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25201154/pubmed" id="25201154" target="_blank">25201154</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Saito J, Yakuwa N, Sandaiji N, et al. Esomeprazole during pregnancy and lactation: esomeprazole levels in maternal serum, cord blood, breast milk, and the infant's serum [published online July 7, 2020]. <i>Breastfeed Med</i>. doi:10.1089/bfm.2020.0175</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33031621">
<a name="33031621"></a>Salloum A, Nasr D, Maalouf D. Dermatologic adverse reactions to proton-pump inhibitors: a synthetized review. <i>J Cosmet Dermatol</i>. 2021;20(4):1073-1079. doi:10.1111/jocd.13763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33031621/pubmed" id="33031621" target="_blank">33031621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31967328">
<a name="31967328"></a>Salloum A, Nasr D, Maalouf D. Esomeprazole fixed drug eruption. <i>Contact Dermatitis</i>. 2020;82(5):334-335. doi:10.1111/cod.13479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31967328/pubmed" id="31967328" target="_blank">31967328</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Saltzman JR. Overview of the treatment of bleeding peptic ulcers. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23960351">
<a name="23960351"></a>Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. <i>Indian J Nephrol</i>. 2013;23(4):304-307. doi:10.4103/0971-4065.114487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23960351/pubmed" id="23960351" target="_blank">23960351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24834779">
<a name="24834779"></a>Sánchez-Morillas L, Rojas Pérez-Ezquerra P, González Mendiola R, Gómez-Tembleque Ubeda P, Santos Alvarez A, Laguna-Martínez JJ. Eleven cases of omeprazole hypersensitivity: diagnosis and study of cross-reactivity. <i>J Investig Allergol Clin Immunol</i>. 2014;24(2):130-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24834779/pubmed" id="24834779" target="_blank">24834779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24547721">
<a name="24547721"></a>Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. <i>Br J Dermatol</i>. 2014;170(2):342-351. doi:10.1111/bjd.12699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24547721/pubmed" id="24547721" target="_blank">24547721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29894542">
<a name="29894542"></a>Schmitz B, Sorrells T, Glass JS. Acute generalized exanthematous pustulosis caused by pantoprazole. <i>Cutis</i>. 2018;101(5):E22-E23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/29894542/pubmed" id="29894542" target="_blank">29894542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35354777">
<a name="35354777"></a>Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. <i>Am J Gastroenterol</i>. 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35354777/pubmed" id="35354777" target="_blank">35354777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21365243">
<a name="21365243"></a>Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. <i>Dig Dis Sci</i>. 2011;56(4):931-950. doi:10.1007/s10620-010-1560-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21365243/pubmed" id="21365243" target="_blank">21365243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23350044">
<a name="23350044"></a>Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. <i>J Neurogastroenterol Motil</i>. 2013;19(1):25-35. doi:10.5056/jnm.2013.19.1.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23350044/pubmed" id="23350044" target="_blank">23350044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20739778">
<a name="20739778"></a>Shukla A, Mahapatra A, Gogtay N, Khopkar U. Esomeprazole-induced photoallergic dermatitis. <i>J Postgrad Med</i>. 2010;56(3):229-231. doi:10.4103/0022-3859.68648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20739778/pubmed" id="20739778" target="_blank">20739778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30910853">
<a name="30910853"></a>Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. <i>BMJ</i>. 2019;364:l536. doi:10.1136/bmj.l536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30910853/pubmed" id="30910853" target="_blank">30910853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17112810">
<a name="17112810"></a>Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. <i>Clin Pharmacol Ther</i>. 2006;80(5):539-548. doi:10.1016/j.clpt.2006.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17112810/pubmed" id="17112810" target="_blank">17112810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221370">
<a name="19221370"></a>Sung JJ, Barkun A, Kuipers EJ, et al, “Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding: A Randomized Trial,” <i>Ann Intern Med</i>, 2009, 150(7):455-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19221370/pubmed" id="19221370" target="_blank">19221370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777150">
<a name="24777150"></a>Sung JJ, Suen BY, Wu JC, et al. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. <i>Am J Gastroenterol</i>. 2014;109(7):1005-1010. doi:10.1038/ajg.2014.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24777150/pubmed" id="24777150" target="_blank">24777150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16181387">
<a name="16181387"></a>Talley NJ and Vakil N, “Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,” <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16181387/pubmed" id="16181387" target="_blank">16181387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32691466">
<a name="32691466"></a>Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. <i>J Intern Med</i>. 2021;289(2):162-178. doi:10.1111/joim.13148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32691466/pubmed" id="32691466" target="_blank">32691466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22745572">
<a name="22745572"></a>Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. <i>Int J Med Sci</i>. 2012;9(5):322-326. doi:10.7150/ijms.4397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22745572/pubmed" id="22745572" target="_blank">22745572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35183361">
<a name="35183361"></a>Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. <i>Gastroenterology</i>. 2022;162(4):1334-1342. doi:10.1053/j.gastro.2021.12.247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/35183361/pubmed" id="35183361" target="_blank">35183361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695179">
<a name="18695179"></a>Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. <i>CMAJ</i>. 2008;179(4):319-326. doi:10.1503/cmaj.071330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18695179/pubmed" id="18695179" target="_blank">18695179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626024">
<a name="9626024"></a>Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. <i>Am J Med</i>. 1998;104(5):422-430. doi:10.1016/s0002-9343(98)00087-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/9626024/pubmed" id="9626024" target="_blank">9626024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19659985">
<a name="19659985"></a>Thakor AS, Burke A, Handfield-Jones S, Sinha A, Palmer M, Burns A. Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. <i>Australas J Dermatol</i>. 2009;50(3):207-210. doi:10.1111/j.1440-0960.2009.00540.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19659985/pubmed" id="19659985" target="_blank">19659985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421-434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28008288">
<a name="28008288"></a>Thomas B, Mohamed M, Al Hail M, et al. A case of probable esomeprazole-induced transient liver injury in a pregnant woman with hyperemesis. <i>Clin Pharmacol</i>. 2016;8:199-202. doi:10.2147/CPAA.S106234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28008288/pubmed" id="28008288" target="_blank">28008288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060319">
<a name="31060319"></a>Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. <i>Int J Environ Res Public Health</i>. 2019;16(9):1571. doi:10.3390/ijerph16091571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/31060319/pubmed" id="31060319" target="_blank">31060319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047577">
<a name="20047577"></a>Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. <i>Aliment Pharmacol Ther</i>. 2010;31(7):754-759. doi:10.1111/j.1365-2036.2009.04229.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20047577/pubmed" id="20047577" target="_blank">20047577</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vakil NB. Approach to refractory or recurrent peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2020c">
<a name="Vakil.2020c"></a>Vakil NB. Overview of complications of peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2020c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.1">
<a name="Vakil.1"></a>Vakil NB. Peptic ulcer disease: treatment and secondary prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30262672">
<a name="30262672"></a>Vangala C, Niu J, Lenihan CR, Mitch WE, Navaneethan SD, Winkelmayer WC. Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis. <i>Clin J Am Soc Nephrol</i>. 2018;13(10):1534-1541. doi:10.2215/CJN.02190218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/30262672/pubmed" id="30262672" target="_blank">30262672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117619">
<a name="24117619"></a>Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, Devault KR, Talley NJ, Achem SR. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1312-1319. doi:10.1111/apt.12513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24117619/pubmed" id="24117619" target="_blank">24117619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24667886">
<a name="24667886"></a>Wade JW. Toxic megacolon after abdominoplasty: a case report. <i>Ann Plast Surg</i>. 2014;72(6):S170-S171. doi:10.1097/SAP.0000000000000180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24667886/pubmed" id="24667886" target="_blank">24667886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821323">
<a name="19821323"></a>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004275. doi:10.1002/14651858.CD004275.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19821323/pubmed" id="19821323" target="_blank">19821323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176276">
<a name="32176276"></a>Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. <i>JAMA Pediatr</i>. 2020;174(6):543-551. doi:10.1001/jamapediatrics.2020.0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32176276/pubmed" id="32176276" target="_blank">32176276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28054368">
<a name="28054368"></a>Wei L, Ratnayake L, Phillips G, et al. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. <i>Br J Clin Pharmacol</i>. 2017;83(6):1298-1308. doi:10.1111/bcp.13205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28054368/pubmed" id="28054368" target="_blank">28054368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33805341">
<a name="33805341"></a>Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of food and dosing regimen on safety and efficacy of proton pump inhibitors therapy-a literature review. <i>Int J Environ Res Public Health</i>. 2021;18(7):3527. doi:10.3390/ijerph18073527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/33805341/pubmed" id="33805341" target="_blank">33805341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142168">
<a name="19142168"></a>Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. <i>J Clin Gastroenterol</i>. 2009;43(6):551-553. doi:10.1097/MCG.0b013e31817d3fa1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19142168/pubmed" id="19142168" target="_blank">19142168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32091544">
<a name="32091544"></a>Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis. <i>JAMA Intern Med</i>. 2020;180(4):561-571. doi:10.1001/jamainternmed.2020.0009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/32091544/pubmed" id="32091544" target="_blank">32091544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wolfe.1">
<a name="Wolfe.1"></a>Wolfe MM. Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference">
                  Wolfe MM and Sachs G, “Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,” <i>Gastroenterology</i>, 2000,118(2 Suppl 1):9-31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22389003">
<a name="22389003"></a>Zaccardi F, Pitocco D, Martini F, et al. A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance. <i>Acta Diabetol</i>. 2014;51(1):151-153. doi:10.1007/s00592-012-0382-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22389003/pubmed" id="22389003" target="_blank">22389003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932360">
<a name="15932360"></a>Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. <i>Aliment Pharmacol Ther</i>. 2005;21(11):1299-1312. doi:10.1111/j.1365-2036.2005.02490.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/15932360/pubmed" id="15932360" target="_blank">15932360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677158">
<a name="16677158"></a>Zargar SA, Javid G, Khan BA, et al, “Pantoprazole Infusion as Adjuvant Therapy to Endoscopic Treatment In Patients With Peptic Ulcer Bleeding: Prospective Randomized Controlled Trial,” <i>J Gastroenterol Hepatol</i>, 2006, 21(4):716-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16677158/pubmed" id="16677158" target="_blank">16677158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17213007">
<a name="17213007"></a>Zhao J, Li J, Hamer-Maansson JE, et al, “Pharmacokinetic Properties of Esomeprazole in Children Aged 1 to 11 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,” <i>Clin Ther</i>, 2006, 28(11): 1868-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17213007/pubmed" id="17213007" target="_blank">17213007</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9104 Version 715.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
